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Abstract  
Leishmaniasis is a disease caused by obligate intracellular parasites of the 
genus Leishmania, including 20 species that are pathogenic to humans. Female sand 
fly is the known vector that can transmit the disease. Visceral leishmaniasis is the 
severe form of the disease that affects internal organs and can be fatal with 
inappropriate diagnosis or treatment. Leishmania donovani is the causative agent of 
visceral leishmaniasis. Approximately 350 million in 89 countries are at risk of infection. 
Around 2 million new cases are reported annually with 500,000 of these are visceral 
leishmaniasis. Current drug therapies are inadequate due to their toxicity, high cost, 
severe adverse reaction, limited availability, and the emergence of resistance.  With all 
these limitations, the need for new drugs is urgent.  
Pentavalent antimonials are the first line of treatment for leishmaniasis since the 
1940s. Although amphotericin B, pentamidine and paromomycin are current drugs that 
treat leishmaniasis, they were discovered initially as a treatment for other pathogens. 
Furthermore, miltefosine the only available oral drug for leishmaniasis is an anticancer 
drug that found to be active against Leishmania. Therefore, we used our quantitative 
Leishmania donovani axenic amastigote assay and the clinically relevant infected 
macrophage assay to identify new antileishmanial hits from unstudied or understudied 
natural product sources such as mangrove endophytic fungi, Antarctic deep-sea coral, 
and terrestrial plants. We also used the same assays to screen synthetic compounds 
form multiple chemical scaffolds. 
	   viii	  
Our well-established assays led to the identification of new antileishmanial hits 
from unstudied natural products and the discovery of new classes of molecules from 
synthetic compounds that possess potent activity against Leishmania donovani. Finally, 
we conducted an in vivo hamster study on an active hit that revealed high efficacy 
against Leishmania donovani in this severe model leading to promising antileishmanial 
drug development. 
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 Chapter One: Introduction 
Abstract 
Leishmaniasis is a disease caused by obligate intracellular parasites of the 
genus Leishmania. The genus includes 20 species that are pathogenic to humans. 
Female sand fly is the known vector that can transmit the disease. Leishmania donovani 
is the causative agent of visceral leishmaniasis. Visceral leishmaniasis is the severe 
form of the disease that affects internal organs and can be fatal with inappropriate 
diagnosis or treatment. Other forms of the disease include cutaneous and 
mucocutaneus. Approximately 350 million in 89 countries are at risk of infection. Around 
2 million new cases are reported annually, of which 500,000 present in the visceral 
form. Current drug therapies are inadequate due to their toxicity, high cost, severe 
adverse reaction, limited availability, and the emergence of resistance.  With all these 
limitations, the need for new drugs is urgent.  
Pentavalent antimonials have been the first line of treatment for leishmaniasis 
since the 1940s. Although amphotericin B, pentamidine and paromomycin are current 
drugs that treat leishmaniasis, they were discovered initially as a treatment for other 
pathogens. Miltefosine, the only available oral drug for leishmaniasis, is an anticancer 
drug that was found to be active against Leishmania. This project investigated new 
antileishmanial hits from unstudied or understudied natural products using quantitative 
Leishmania donovani axenic amastigote assay and the clinically relevant infected 
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macrophage assay. Natural project sources include mangrove endophytic fungi, 
Antarctic deep-sea coral, and terrestrial plants. Additionally, the same assays were 
used to screen synthetic compounds from multiple chemical scaffolds. 
Our well-established assays led to the identification of new antileishmanial hits 
from unstudied natural products and the discovery of new classes of molecules from 
synthetic compounds that possess potent activity against Leishmania donovani. Finally, 
we conducted an in vivo hamster study on an active hit that revealed high efficacy 
against Leishmania donovani in this severe model leading to promising antileishmanial 
drug development. 
Leishmania: Background  
Most parasitic diseases are neglected in the developing world, but represent 
significant burdens in areas of poor health, poor access to healthcare, and overwrought 
infrastructures due to war or social unrest lead. These combination of factors are 
favorable to the establishment of recurrent epidemic cycles of transmission. Although 
leishmaniasis is one of these neglected diseases, vectors responsible for transmitting 
the disease is not associated with living conditions; thus controlling this disease is a 
challenge (Beyrer et al., 2007). Leishmania is an obligate intracellular protozoan 
parasite with a divalent life cycle. Its flagellated promastigote stage is found in the 
sandfly vector, and inside the macrophages of the host (animals-humans) an 
amastigote stage with a truncated flagellum is found. This devastating parasite belongs 
to the Leishmania genus (Domain Eukaryota, Phylum Euglenozoa, Class 
Kinetoplastida, Order Trypanosomatida) (Neuber, 2008).  
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According to estimates by the World Health Organization (WHO), leishmaniasis 
collectively affects 12 million people around the globe. Approximately 310 million 
additional people worldwide are at risk of infection (Neuber, 2008). The disease is 
spread by the bite of female sand flies (definitive host) of the genera Lutzomyia (new 
world) and Phlebotomus (old world), although the taxonomic status of some of them is 
disputed, 20 different species of flagellated unicellular protozoa belonging to the genus 
Leishmania are known to infect these sand flies. In fact, there are approximately 600 
sand-fly species, but only 10% of them can act as vectors of leishmaniasis (Sharma & 
Singh, 2008). The female sand-flies require blood meals to obtain protein for their egg 
broods and typically will travel several hundred meters from their habitat at night and 
dusk to feed (Sharma & Singh, 2008).  
The parasite affects people of many cultures in the world which has resulted in 
multitude of names for the disease including: Aleppo boil, Valley sickness, Andean 
sickness, Leprosy of the mountains, White Leprosy, DumDum fever, Kala-azar (black 
fever), Grayish, Assam fever, and Jericho buttons (James, Elston, & Berger, 2011). 
Human and animals have been infected with the Leishmania parasite for at least 4000 
years as manifest by positive amplification of Leishmania kinetoplast DNA in Egyptian 
and Nubian mummies (Zink et al., 2006). William Boog Leishman discovered the 
causative agent of leishmaniasis in 1903, when he examined the oval bodies 
(amastigotes) found in the spleen of a British soldier who died from DumDum fever in 
India (Leishman, 1903). Independently, Charles Donovan found oval bodies 
(amastigotes) in patients who died from leishmaniasis. Accordingly, Ronald Ross 
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suggested that this newly discovered organism be named after these two men who 
discovered the causative agent of this disease (Ross, 1903).  
Since this discovery, over one-hundred-years of research has been devoted to 
studying Leishmania including epidemiology, host-parasite interactions, as well as drug 
and vaccine discovery. Because it is a neglected tropical disease and a particularly 
complicated organism, progress has been slow (Zink et al., 2006). The pathology of 
Leishmania donovani was first described in detail by Christophers (1904), the finding 
showed that parasites proliferate in macrophages and aggregate in the liver, spleen, 
and bone marrow (Christophers, 1904). Learning how to culture Leishmania was the 
first step to study this parasite in the lab. In 1904, Rogers was the first to grow 
Leishmania, but the cultures could only survive for 2 weeks (Rogers, 1904). In 1909 Ch. 
Nicolle used Novy-McNeal medium that was used to grow Leishmania for a couple of 
weeks and modified it into Nicolle-Novy- McNeal (NNM) medium which consists of 
bacto beef, neopeptone, bacto agar, and rabbit blood to subculture Leishmania 
indefinitely (Row, 1912; Wang et al., 2010).  
Meleney (1925) infected hamsters from in vitro cultures, and studied the 
progression of the disease, and many species were capable of being infected with 
Leishmania (Croft, Seifert, & Yardley, 2006). Because hamsters have a similar 
physiological response to humans in regards to the progression of the disease, they 
became an important model organism for studying L. donovani (Simon L Croft, Shyam 
Sundar, & Alan H Fairlamb, 2006; Melby, Chandrasekar, Zhao, & Coe, 2001). Stauber 
in 1958 developed a method to quantify accurately parasite burden in the tissues of 
these hamsters. He took impression smears of infected organs and determined 
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Leishman Donovan Units (LDU), which is calculated as organ mass (g) multiplied by the 
number of amastigotes per one thousand macrophage nuclei. The development of the 
LDU method established a standard method to evaluate drug effectiveness in vivo that 
is still in use today (Stauber, 1958).  
Leishmania Life Cycle  
The parasite may follow two different transmission cycles: zoonotic cycle and 
anthroponotic cycle. In the zoonotic cycle, dogs are a vital animal reservoir in addition to 
other mammals; while in the strictly anthroponotic cycle, humans are the only host, 
which is typically observed in densely inhabited urban areas (Lainson & Shaw, 2010).  
  Leishmania life cycle (Figure 1.1) mainly depends on the exchange of two 
morphological forms; promastigotes (Figure 1.2) in sand fly vector and amastigotes 
(Figure 1.3) in the mammalian host cells. Promastigotes can differentiate into different 
forms inside the sand fly. Its growth cycle starts with the dividing procyclic form in the 
abdominal midgut of the sand fly during a blood meal. Then it transforms into the non-
dividing nectomonad form, which is responsible for the migration of the infection and 
transforms into leptomonad form in the anterior midgut. Leptomonads transforms into 
the infectious form, metacyclic promastigote (Gossage, Rogers, & Bates, 2003). The 
infectious metacyclic promastigotes are then injected into the host’s body by the bite of 
female sand fly during a blood meal, which are then taken up by macrophages where 
the parasite transforms into the pathogenic tissue stage (amastigote). The latter form 
then multiplies asexually and infects other macrophages. Finally, the sand fly gets 
infected during a blood meal by ingesting infected cells with amastigotes, which then 
transform into promastigotes in the sand fly gut. Until recently, promastigotes were 
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believed to undergo asexual division inside the sand fly. In 2009 Akopyants et al. 
discovered the ability of promastigotes to go through sexual division inside the sand fly 
(Akopyants et al., 2009). 
Clinical Manifestations 
Clinical disease due to Leishmania presents in three major forms: visceral 
leishmaniasis, cutaneous leishmaniasis, and mucocutaneous leishmaniasis. 
Visceral leishmaniasis is a systemic severe form of the disease that can be fatal 
if left untreated (Kumari & Ram, 2002), (Nagle et al., 2014). The main clinical features 
include enlarged liver and spleen, severe anemia, weight loss, and prolonged fever 
(Hirve et al., 2017), (Guerin et al., 2002). These symptoms usually appear 3 to 6 months 
post infection. In some cases, it takes years for the disease to manifest, where 
asymptomatic patients remain undiagnosed unless they become immunocompromised 
then the symptoms will appear (Polak et al., 2012). Darkening of the skin is another 
clinical feature of VL and mainly occurs in South Asia and called Kala-azar, which 
means black fever in the Hindi language (Dorlo, Balasegaram, Beijnen, & de Vries, 
2012) (Sacks et al., 1995). Post Kala-azar dermal leishmaniasis (PKDL) is a dermal 
form of leishmaniasis and can appear months or years after a successful treatment of 
visceral leishmaniasis (Redhu, Dey, Balooni, & Singh, 2006), (Burza et al., 2014) 
(Sundar & Chakravarty, 2013). PKDL is characterized by papule skin lesions on the 
face that increase in size over time, then spread all over the body as nodules and 
requires prolonged chemotherapy (R. P. Singh et al., 2012). The clinical feature of 
PKDL depends on the geographical distribution of the disease. In Indian subcontinent, 
PKDL is rare and the nodules transform into plaques (Zijlstra, Alves, Rijal, Arana, & 
	  
	  
7	  
Alvar, 2017). While in East Africa, PKDL is more frequent and the nodules become 
ulcers. In some cases, PKDL can cause blindness or nerve damage (Rijal, Agrawal, 
Agarwalla, Agrawal, & Rijal, 2005), (R. Singh et al., 2006), (Zijlstra, Musa, Khalil, el-
Hassan, & el-Hassan, 2003), (el Hassan et al., 1992). Furthermore, PKDL patients may 
act as a reservoir hosts since the nodules contain Leishmania parasites and can be 
picked up by sandflies (Gupta & Nishi, 2011; Roatt et al., 2014; Wang et al., 2010).  
Patients with visceral leishmaniasis are at high risk of developing bacterial infections 
such as pneumonia and gastrointestinal infection (Pasyar, Alborzi, & Pouladfar, 2012), 
(Andrade, Carvalho, & Rocha, 1990). Moreover, HIV patients are more likely to develop 
visceral leishmaniasis at a rate approximately 2000 times more when compared to non- 
HIV infected individuals (Pineda et al., 1998), (Lindoso, Cunha, Queiroz, & Moreira, 
2016).  
Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis. CL is 
caused by both New World and Old World species of Leishmania and the symptoms of 
the disease depend on the Leishmania species and the mode of transmission. The 
disease manifests as ulcerative lesions that develop at the site of the sand fly bite, 
which can grow progressively larger and fail to heal naturally (Salman, Rubeiz, & Kibbi, 
1999). These lesions often appear on exposed areas of the body such as the face, and 
are associated with significant social stigma and disability. If infected with bacteria, 
these lesions can be quite painful (Layegh et al., 2015). Lymphadenopathy often 
precedes appearance of the lesion. Even with this localized form of the disease, often 
multiple satellite lesions appear, and can persist for months or years (Harms, Fraga, 
Batroff, Oliveira, & Feldmeier, 2005). Successful treatment does not eliminate the 
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noticeable scars that remain visible for life (Markle & Makhoul, 2004). Diffuse cutaneous 
leishmaniasis (DCL) is a rare condition characterized by multi non-ulcerated nodules 
with high parasite load. It is seen in HIV infected persons and occurs due to immune 
system deficiency (Sinha, Fernandez, Kapila, Lambert, & Schwartz, 2008). 
Mucocutaneous leishmaniasis (MCL) is a severe mutilating rare form of the 
disease, which typically occurs as a metastatic dissemination of the parasite from the 
site of initial infection on the skin to mucosal membranes of the body, primarily around 
the nose and mouth (Markle & Makhoul, 2004), (Kedzierski, 2011). This disease also 
known as espundia and Breda (Neuber, 2008). Complete ulcerative destruction of the 
oropharyngeal tissues is often seen in the absence of timely treatment. The first 
symptoms such as persistent nosebleeds may appear several months or even years 
after the healing of the primary skin lesion. Other symptoms include; fever, 
lymphadenopathy, enlarged liver. Severe cases of MCL may experience complications 
within the nasal cavity including edema, septum perforation in addition to periodontitis 
and destruction of oronasopharyngeal mucosa and obstruction of the airway. This 
condition can be life-threatening (Diniz, Costa, & Goncalves, 2011). The disease 
pathogenesis is poorly understood, and is often associated with lack of appropriate 
treatment of cutaneous lesions (Moreira et al., 2016). However, a recent study linked 
the aggressive phenotype of MCL to the presence of Leishmania RNA virus (Zangger et 
al., 2013). Leishmania RNA virus is a Totiviridae double stranded RNA virus presented 
in several Leishmania parasites’ species and serve as a natural host for the virus 
(Hartley, Ronet, Zangger, Beverley, & Fasel, 2012) (Adaui et al., 2016). Furthermore, 
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host genetics factors may play an important role in the progression of the disease 
(Mangano & Modiano, 2014). 
Diagnosis 
The management of leishmaniasis is reliant upon a proper diagnosis. However, 
the diagnosis of the disease is a challenge and misdiagnosis may resulted in an 
unfavorable outcome (Handler, Patel, Kapila, Al-Qubati, & Schwartz, 2015b) 
Microscopic examination is mainly used to diagnose visceral leishmaniasis by 
visualizing amastigotes in samples collected from the lymph node, spleen aspiration, 
and bone marrow. This method is used to diagnose the disease and to evaluate the 
effectiveness of the treatment (Sakkas, Gartzonika, & Levidiotou, 2016). PCR can be 
used to determine the infecting parasite species and for quantification assessment of 
parasite burden by amplifying Leishmania gene targets such as ß tubulin, kinetoplast 
DNA, and cytochrome b (Osman et al., 1997). Furthermore, serological tests such as 
indirect immunofluorescence assay test, direct agglutination test, and fast agglutination 
screening test are used to monitor specific antileishmanial antibodies (Lockwood & 
Sundar, 2006). On the other hand, antigen detection tests are used as an alternative to 
antibody detection, which has high specificity but low sensitivity (Vallur et al., 2015), 
(Boelaert et al., 2014). The parasite burden has shown to be 10-fold higher in VL/ HIV-
positive patients compared to VL/ HIV-negative patients; therefore, direct microscopic 
examination and quantitative tests are highly sufficient and sensitive for the diagnosis of 
HIV/VL coinfected patients (van Griensven, Carrillo, Lopez-Velez, Lynen, & Moreno, 
2014). In PKDL patients, the sample collection method of tissue biopsy is invasive, and 
the number of parasites is low in the papulae, which complicate the detection of the 
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infection. Also, misdiagnosis of leprosy is not uncommon in PKDL patients (el Hassan, 
Hashim, Abdullah, Zijlstra, & Ghalib, 1993). Therefore, the diagnosis of PKDL mainly 
relies on the previous history of VL and its serological tests (Salotra & Singh, 2006).  
Cutaneous leishmaniasis is diagnosed by visual microscopic examination of the 
parasites on samples collected from skin scraping of ulcer margins, punch biopsy or 
needle aspirate. PCR quantification, serological tests and antigenic tests are also used 
to diagnose CL (de Vries, Reedijk, & Schallig, 2015) 
Mucocutaneous leishmaniasis is diagnosed by physical examination and medical 
history evaluation by a healthcare provider. Serological tests along with PCR and DNA 
testing can be used to confirm the infection (Handler et al., 2015b). 
Improved diagnostic tests with low cost, less invasive sample collection; high 
sensitivity and specificity are much needed for better diagnosis of the disease (Nagle et 
al., 2014). 
Epidemiology 
 The accurate epidemiological data from many endemic countries is lacking 
(Jorge Alvar et al., 2012). Thus the actual burden of the disease may be higher than 
official WHO estimates, especially if the mental health repercussions, in the form of 
social stigma and ostracization associated with some clinical manifestations, are 
appropriately factored in (Lainson & Shaw, 2010). Asymptomatic cases may act as 
significant reservoir for re-infection as it is known to exist in endemic areas (O. P. Singh, 
Hasker, Sacks, Boelaert, & Sundar, 2014). 
Visceral leishmaniasis has two forms differ in the causative Leishmania species 
and the parasite reservoir. Leishmania infantum causes the zoonotic form of VL and 
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occur mainly in the Mediterranean basin and Central and South America. In this form, 
dogs are the main parasites reservoir (Quinnell & Courtenay, 2009),(Shimozako, Wu, & 
Massad, 2017). The other form of VL is caused by Leishmania donovani and found in 
India, Nepal, Bangladesh and East Africa (Guerin et al., 2002), (Tchokouaha Yamthe et 
al., 2017), (Ready, 2014). VL has been reported in 98 countries around the globe with 
approximately 300,000 new cases occur annually leading to 40,000 deaths, although 
the real number may be higher due to poor epidemiological surveillance in many areas 
of active transmission (Leta, Dao, Mesele, & Alemayehu, 2014). 90% of new VL cases 
are concentrated in 6 countries: Bangladesh, India, Ethiopia, Sudan, South Sudan, and 
Brazil (Gupta & Nishi, 2011), (de Araujo et al., 2013) and round 60% of reported new 
cases occur in Bihar state in India (Hasker et al., 2012). The absences of proper control 
measures make VL a serious public health issue (Nagle et al., 2014). 
Cutaneous leishmaniasis is estimated to infect around 1.3 million new patients 
each year worldwide according to the WHO Global Health Observatory (Vitoriano-
Souza et al., 2008). Approximately 70% of the cases occur in ten countries: Sudan, 
Afghanistan, Ethiopia, Algeria, Iran, Syria, Brazil, Peru, Costa Rica, and Colombia (J. 
Alvar et al., 2012). There is an increased risk of CL incidents due to military work, travel 
and immigration from endemic areas (Khan et al., 2016). About 40% of reported CL 
cases in the USA are from tourists who traveled to Central and South America and 
military who served in endemic areas (Herwaldt & Berman, 1992). In the New World, 
around 60% of skin diseases are due to CL (Pavli & Maltezou, 2010).  
Different Leishmania parasite species cause CL and that include: Leishmania 
mexicana, Leishmania amazonensis, Leishmania braziliensis, Leishmania panamensis, 
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Leishmania guyanensis, Leishmania aethiopica, Leishmania venezuelensis, Leishmania 
lainsoni, Leishmania shawi, Leishmania peruviana, Leishmania naiffi, Leishmania 
lindenbergi, Leishmania. martiniquensis and  Leishmania waltoni in the New World and  
Leishmania tropica, Leishmania aethiopica and Leishmania major in the Old World 
(Tchokouaha Yamthe et al., 2017). 
 Mucocutaneous leishmaniasis mostly occurs in South America, specifically in 
Brazil, Paraguay, Ecaudor, Bolivia, Peru, Colombia and Venezuela. Around 90% of the 
cases occur in Peru, Brazil and Bolivia (Handler, Patel, Kapila, Al-Qubati, & Schwartz, 
2015a), (Grogl, Oduola, Cordero, & Kyle, 1989). MCL is caused by New World species 
of Leishmania belonging to the Viannia subgenus, namely Leishmania Viannia 
braziliensis, Leishmania Viannia panamensis, Leishmania Viannia guyanensis, and 
sometimes L. amazonensis (Tchokouaha Yamthe et al., 2017), (Bilbao-Ramos et al., 
2017). 
Current Treatments 
 Due to the absence of a vaccine against Leishmania, chemotherapy is the only 
choice for treatment. Drug development against Leishmania is challenging because an 
active drug needs to have the ability to pass through several membranes to reach the 
target. It also must maintain the pH changes to get into the parasite. Therefore, there 
are a limited number of available drugs to treat leishmaniasis. However, these available 
drugs suffer from limitations. The recommended treatment of visceral leishmaniasis is 
different between endemic regions (Nagle et al., 2014). In Africa, the WHO 
recommends a combination of pentavalent antimonials and parmomycin to treat visceral 
leishmaniasis (Berman, 2006). On the other hand, in South Asia, a combination of a 
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single dose of liposomal amphotericin B and a short course miltefosine is effective. In 
rich countries, liposomal amphotericin B is the drug of choice (Moore & Lockwood, 
2010). In South America, meglumine antimoniate is the treatment of choice for mild and 
severe cases of visceral leishmaniasis, while liposomal amphotericin B is used for 
severe cases and pregnant women (Romero et al., 2017).  
Pentavalent Antimonials: for decades, Antimony based compounds have been 
used to treat leishmaniasis. Brahmachari discovered the effectiveness of the 
pentavalent antimony compound urea stibamine against VL in 1925, which saved 
millions of infected individuals with VL especially in India (Marsden, 1986). Later on, in 
1937 Solustibosan an antimony gluconate compound was synthesized. Besides, in 
1945 Pentostam a sodium stibogluconate compound was discovered and used as an 
antileishmanial drug as well (Haldar, Sen, & Roy, 2011). Sodium stibogluconate 
(Pentostam) and meglumine antimonite (Glucantime) are the two currently used 
formulations of pentavalent antimonials that are used as a treatment for leishmaniasis. 
Both formulations suffer from difficult administration route (intramuscular injection or 
intravenous infusions) (Kato et al., 2014). Pentavalent antimonials are still used as the 
first-line drugs in many countries to treat all forms of leishmaniasis. However, they have 
several limitations such as prolonged treatment time that causes pain in the injection 
site, severe side effects (toxicity in the heart, liver and pancreas), drug resistance and 
the requirement of medical supervision. Apparently, VL/HIV positive patients are at 
higher risk of toxicity and mortality caused by the use of antimonials compared to 
VL/HIV negative patients treated with antimonials, or VL/HIV positive patients treated 
with amphotericin B or miltefosine (Ritmeijer et al., 2006). The mechanisms of 
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pentavalent antimonials are not fully understood and it is not clear if the final active form 
is Sb(V) or Sb(III). However, there are two main proposed mechanism of actions. The 
prodrug model where pentavalent antimonials Sb(V) is reduced to trivalent antimonials 
Sb(III) by macrophages or amastigotes in order to act as an antileishmanial agent 
(Frezard, Demicheli, Ferreira, & Costa, 2001). On the other hand, according to active 
pentavalent antimonials model, Sb(V) possess intrinsic antileishmanial activity (Walker 
& Saravia, 2004). Other studies showed that the level of expression of AQP1 
transporter my play a role in parasite resistance against Sb(III) (Gourbal et al., 2004). In 
the early 2000s, the efficacy of antimonials decreased in India and more than 60% of VL 
infected patients in Bihar state did not respond to the treatment (Sundar et al., 2000). It 
is still not clear what causes the emergence of antimony resistant Leishmania donovani 
in Bihar state. A misuse of the drug might be behind the emergence of antimonials 
resistance. In another hypothesis, groundwater in Bihar state was contaminated with 
naturally occurring trivalent arsenic. Therefore, Bihar population was chronically 
exposed to low concentration of arsenic in drinking water, which may have led to the 
resistance in the Bihar population (Perry et al., 2015). The resistance to antimonials in 
India encouraged the development of other drugs. Antimonials are also used to treat 
cutaneous leishmaniasis and mucocutaneous leishmaniasis as well (Minodier & Parola, 
2007). 
Miltefosine: Miltefosine is an alkyle-phospholipid that is known as an anticancer 
drug (Dorlo et al., 2012).  Miltefosine was tested against Leishmania and exhibited an 
exceptional activity, which was then approved to be the first oral VL treatment in India in 
2002 (Sundar et al., 2012). The most common side effects of miltefosine are vomiting, 
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nausea, diarrhea, decreased appetite, headache and liver toxicity. Teratogenicity is 
another limitation of miltefosine (Tiwari, Gedda, Tiwari, Singh, & Singh, 2018). The 
mechanism of action is partially known as most studies were conducted on tumor cell 
lines. It is suggested that miltefosine induces apoptosis (Cell death) (Verma & Dey, 
2004), (Paris, Loiseau, Bories, & Breard, 2004) and inhibit the synthesis of phosphatidyl 
choline (Wright, Howe, & Zaremberg, 2004), (Cui & Houweling, 2002). Recently, a study 
showed a decline in miltefosine efficacy with a decreased cure rate of around 90% and 
miltefosine resistance has been reported (Sundar et al., 2012), (Srivastava et al., 2017). 
There are several reported studies of lab induced miltefosine resistant Leishmania 
strains. One study showed that the transporter LdMT (P-type ATPase) is responsible for 
the translocation of miltefosine and the mutations in this gene were observed in the 
resistant strain (Perez-Victoria, Gamarro, Ouellette, & Castanys, 2003). It was also 
found that the overexpression of LiABCG4 leads to drug efflux resulting in resistance 
(Castanys-Munoz, Alder-Baerens, Pomorski, Gamarro, & Castanys, 2007). 
Amphotericin B: In 1955, Amphotericin B was discovered as an antifungal drug. 
It was isolated from Streptomyces nodosus as a polyene antibiotic (Donovick, Gold, 
Pagano, & Stout, 1955). Then in 1960, the antileishmanial activity was reported, and a 
successful treatment against visceral leishmaniasis was achieved in 1963 in Brazil 
(Nagle et al., 2014), (Furtado, Cisalpino, & Santos, 1960), (Adler, 1964). This drug is the 
first line treatment for visceral leishmaniasis in the Mediterranean region. It is also the 
drug of choice for HIV/LV co-infection. Amphotericin B can be given as deoxycholate or 
as various lipid formulations. The main limitations of the deoxycholate form of the drug 
are infusion reactions (fever, chills, and thrombophlebitis), severe toxicity (myocarditis, 
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nephrotoxicity, and some times, death). These serious side effects require 
hospitalization for close monitoring, thus increasing the cost of the treatment and 
limiting the access for infected individuals. However, Lipid formulation of amphotericin B 
is less toxic but more expensive (Sundar & Chakravarty, 2010), (Messori, Fadda, 
Maratea, Trippoli, & Marinai, 2013). Amphotericin B is believed to bind to ergosterol in 
the cell membrane leading to the loss of membrane integrity resulting in cell death 
(Matsumori et al., 2009). Resistance to amphotericin B has recently emerged in the field 
(Purkait et al., 2012). A study showed that the significant sterol in amphotericin B 
resistant parasite was cholesa-5, 7, 24-trien-3β-ol, while the major sterol in amphotericin 
B sensitive parasite was ergosterol, which is the drug target (Purkait et al., 2012).  
Paromomycin: Paromomycin is an aminoglycoside- aminocyclitol antibiotic that 
was isolated from Stryptomyces krestomuceticus in the 1950s. It is believed that 
parmomycin binds to 16S rRNA inhibiting the proteosynthesis (Vicens & Westhof, 
2001). This drug was first used as a treatment for cutaneous leishmaniasis in 1966, and 
for visceral leishmaniasis since 1990 in Kenya (Nagle et al., 2014). The most significant 
side effect is pain at the injection site. Ototoxicity and an elevation of liver 
transaminases were reported (Sundar, Jha, Thakur, Sinha, & Bhattacharya, 2007). A 
randomized vehicle-control phase 3 trial of topical Paromomycin treatment with and with 
out gentamicin for cutaneous leishmaniasis was conducted in Tunisia.  The cure rate of 
index lesion was 81% and 82% for paromomycin-gentamicin and paromomycin alone 
respectively (Ben Salah et al., 2013).  
Pentamidine: Pentamidine is being has been used for treatment of sleeping 
sickness since the 1940s (Rollo, Williamson, & Lourie, 1949) (Nagle et al., 2014). It was 
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first used as a treatment of VL in India in 1949 (Hazarika, 1949), and in Spain in 1950 
(Martinez Garcia, Guasch, & Llaurado, 1950), (Nagle et al., 2014). The most serious 
and irreversible side effect of pentamidine is hypoglycemia. Therefore, it has to be given 
with extra care, particularly with diabetic patients (Bouchard et al., 1982). Other adverse 
effects include renal toxicity, hypotension and fever (Lai, Vrede, Soetosenojo, & Lai, 
2002). Pentamidine is the drug of choice in French Guiana, and in Suriname (Roussel 
et al., 2006). Until recently, pentamidine was used as a second option drug to treat VL 
cases that did not respond to antimony treatment in India. However, the use of this drug 
was discontinued due to its toxicity and resistance and was replaced with amphotericin 
B (Sundar et al., 2001).  
Azoles: Azoles are oral drugs that treat fungal infections. The main mechanism 
of action is inhibition of ergosterol biosynthesis that leads to the accumulation of 14 α–
methyl sterols. Since Leishmania parasites share the biosynthesis of ergosterol with 
fungi, azoles antileishmanial activity was evaluated. Ketoconazole and itraconazole are 
being used as drugs against leishmaniasis with high efficacy (S. L. Croft, S. Sundar, & 
A. H. Fairlamb, 2006). 
Drug Combination Therapies: Due to the few options of currently available 
antileishmanial drugs and their limitations, drug combination therapy with available 
treatments are being used as a fast approach to overcome these issues. A combination 
of sodium stibogluconate and paromomycin treatment was used in Bihar state and East 
Africa, and exhibited a high cure rate (Musa et al., 2012), (Thakur et al., 1992). 
Sequential use of different drugs was also used as another fast and safe approach of 
combination therapies. A study in India showed that a single infusion of AmBisome (5 
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mg/kg) followed by miltefosine (50 mg/kg/day) for 7 days or paromomycin (11 
mg/kg/day) for 10 days displayed a 97.5% cure rate 6 months post treatment (Sundar et 
al., 2012). 
Vaccine 
 There are various reasons that make the idea of producing an effective vaccine 
against Leishmania possible. The parasite does not undergo genetic variations, 
macrophages are the single host cell, and amastigotes are the only pathogenic stage of 
the disease (Reed, Coler, Mondal, Kamhawi, & Valenzuela, 2016), (Vijayakumar & Das, 
2018). People in endemic areas have demonstrated acquisition of long-life immunity to 
the disease by injecting themselves with Leishmania lesion exudate (Khamesipour, 
Rafati, Davoudi, Maboudi, & Modabber, 2006). The historical practice of 
“leishmanization,” whereby live parasites that cause CL are inoculated in the skin in a 
cosmetically acceptable part of the body, is the only fully effective way to gain immunity 
to CL. The fact that individuals who fully recover from VL are then resistant to re-
infection suggests that immunity to symptomatic visceral disease can be achieved via 
vaccination (Costa et al., 2011). Despite the tremendous work in the field to generate an 
effective vaccine against Leishmania, to date, there is no active vaccine for humans in 
the market yet. LEISH-F1 was the first vaccine that made it to phase I and II clinical 
trials and it has shown its effectiveness and safety.  In addition, LEISH-F2 is a redesign 
to LEISH-F1 to overcome regulatory concern and enhances the manufacture process. 
This later vaccine has been evaluated in phase I and II clinical trials and was safe. 
Recently, LEISH-F3 was developed and successfully evaluated in phase I showing high 
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immunogenicity and safety. In addition, third generation vaccine for VL and PKDL was 
reported recently (Vijayakumar & Das, 2018). 
Leishmania Drug Targets 
 Identifying a suitable drug target from a biological pathway is one of the major 
first steps in drug discovery projects. A molecular target can be enzymes, receptors, 
RNA, transcription factors and ion channels that present in the pathogen with biological 
activity linked to the disease (Hosen et al., 2014). The availability of the genome 
sequences of both Leishmania major and Leishmania infantum has disclosed 
information that can help in the identification of distinctive novel drug targets to these 
parasites. Fortunately, trypanosomatids are branched out quite early from the higher 
eukaryotes in the genetic phylogram. In fact, there are several cellular processes and 
metabolic pathways that are unique to the Leishmanial parasites that do not exist in the 
mammalian host. Thus, these pathways can be used as potential drug targets against 
Leishmania (Chawla & Madhubala, 2010). There are several important criteria to follow 
when selecting a target in a pathogen for drug development. A target must either not be 
present in the host or entirely divergent from the host homolog. It also should be 
essential for the survival of the pathogen and should be demonstrated in the host stage 
rather than the vector stage. Furthermore, the target gene should be expressed in the 
stage of the life cycle that is pathogenic to the host. Besides, it is crucial that the 
selected target has high assay ability in order to evaluate its efficacy (Frearson, Wyatt, 
Gilbert, & Fairlamb, 2007), (Vijayakumar & Das, 2018).  
 There are several unique metabolic pathways for trypanosomes that are absent 
in humans, making them good target for drug development against leishmaniasis. 
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Those include, SMT enzyme in the sterol (ergosterol) pathway, Glycolytic pathway, and 
enzymes involved in the trypothione synthesis pathway (Vijayakumar & Das, 2018). 
Drug Discovery 
 Drug discovery is a process where potential new medicines are identified. 
Collaboration between academia and industry is required for a successful process. This 
process can take up to 15 years and cost over $1 billion (Hughes, Rees, Kalindjian, & 
Philpott, 2011), (Figure 1.4). Hit identification and lead discovery are one of the first 
steps in drug discovery after target identification and validation. In these steps, 
screening assays are applied (Figure 1.5). A hit molecule is defined as a compound with 
a desired activity when screened against the pathogen of interest and its activity is 
confirmed by retesting. There are a wide variety of screening strategies that are used to 
identify hit molecules and that include high throughput screening (large number of 
compounds screened in 384-well plates by complex laboratory automation), focused 
screen (compounds with similar structures or previously identified as hitting specific 
classes of targets), Fragment screen (obtain compounds with small mM activity), 
structural aided drug design, virtual screen, physiological screen, NMR screen (screen 
small compounds by soaking into protein targets of known crystal), and phenotypic 
screen. After hit confirmation by retesting, several compounds will be chosen for further 
exploration such as testing analogues to define Quantitative structure- activity 
relationship (QSAR). Up on QSAR confirmation, selected compounds will undergo lead 
optimization. In this phase, lead compounds are synthesized. A lead compound is 
defined as a chemical compound with a desirable pharmacological or biological activity 
to become a useful therapy. Lead compound structure may require chemical 
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modification to become a better fit to the target such as improve selectivity, potency and 
pharmacokinetic parameters (Frearson & Collie, 2009). The desirable characteristics for 
an ideal compound candidate in drug discovery are: show high affinity to the target (< 1 
µM), has small molecular weight and lipophilicity, does not interfere with P450 enzyme 
or with P-glycoprotiens, chemically tractable, does not bind to human serum albumin, 
stable, drugable (druglikness), water soluble, rapidly metabolized, highly selective, 
demonstrate no cytotoxicity, and show cell membrane permeability (Hughes et al., 
2011). 
Leishmaniasis treatment relies mainly on therapeutic drugs. Currently available 
drugs suffer from various limitations such as toxicity, questionable efficacy, resistance, 
and high cost. Hence, new effective and affordable drugs are urgently needed (Giarolla 
& Ferreira, 2015). Regardless of the significant patient's population, there is limited 
available funding that supports the development of new antileishmanial treatments. 
Therefore, there have been tremendous efforts to repurpose drugs that treat different 
diseases to reduce the cost of developing a new effective drug against leishmaniasis 
(Handler, Patel et al. 2015).  This strategy proved to be successful as several currently 
available antileishmanial medicines such as miltefosine, amphotericin B, and 
pentamidine were previously designed and approved to treat other diseases (Ashburn & 
Thor, 2004), (Novac, 2013). Identification of drug target is another significant approach 
in Leishmania drug discovery as it produces more specific results (Chawla & 
Madhubala, 2010). Moreover, screening chemical libraries is the most used and 
affordable approach when searching for novel antileishmanial hits. 
Screening Applications Used in Drug Discovery  
	  
	  
22	  
The identification of novel hits to undergo further development is a significant 
challenge in drug discovery project. Hit identification, lead optimization, suitable 
physiochemical properties and pharmacokinetic profile are initial steps in the drug 
discovery process and are required to increase the chances of developing compounds 
with high potency and selectivity to the target of interest (Andricopulo, Salum, & 
Abraham, 2009). There are several medicinal chemistry approaches that can be used to 
identify hits and generate leads such as structure based drug design (SBDD), receptor 
based pharmacophore model, molecular docking methods and structure based virtual 
screening. Other experimental methods include high throughput screening, structure 
activity relationship studies of biologically interested molecules, and fragment-based 
screening. The application of computational methods can improve the process of drug 
discovery with reduced cost and time efficient manner (Heifetz, Southey, Morao, 
Townsend-Nicholson, & Bodkin, 2018), (Njogu, Guantai, Pavadai, & Chibale, 2016). 
Moreover, bioinformatics is being used as an approach to accelerate the process of 
drug development. Besides, microarrays and proteome analysis of the complete 
genome, whenever available, provide valuable information in drug development by 
selecting novel enzymes and receptors that are specific for the parasites (Vijayakumar 
& Das, 2018). Most novel compounds against infectious diseases were identified by 
phenotypic drug discovery screening assays, but until recently, it was not the case when 
searching for promising hits against Leishmania due to the complexity of the biology of 
the parasite. However, new and improved technologies made it possible to identify 
novel agents against Leishmania.  
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 Improved in vitro and in vivo systems are being used for hit identification and 
lead optimization. The improved technologies allowed mammalian stage amastigotes 
and the sand fly stage promastigotes to be grown in axenic conditions. Therefore, direct 
drug screening methodologies against these stages can be applied. In vitro testing is 
considered quick, relatively cheap, and the results are consistent. However, the results 
generated from the in vitro system always need to be confirmed in animal studies (in 
vivo).  
The intracellular amastigotes model is the most clinically relevant in vitro testing 
for screening compounds against Leishmania parasites to identify hits. It reflects the 
drug efficacy in the parasite natural environment since it can evaluate the drug ability to 
pass through the host cell membrane and test its effects on the parasites. In this model, 
murine peritoneal macrophages or human monocyte transformed macrophages (THP-1) 
are used as host cells. The drug activity can be then assessed by automated image 
analysis that counts the number of amastigotes per macrophage and generates IC50 
(Siqueira-Neto et al., 2012), (Gupta & Nishi, 2011).   
The axenic amastigotes model is also used in screening compounds against 
Leishmania. This model tests the direct effect of compounds on the parasites but does 
not test its ability to penetrate the host cell or the effect of macrophage environment on 
the activity of tested compounds. Moreover, axenic amastigotes may express different 
metabolic process than intracellular amastigotes (Gupta & Nishi, 2011). There are 
several methods used to assess the activity of screened compounds against axenic 
amastigotes: viability of cells (cellTiter 96 non-radioactive cell proliferation based 
method), (Sereno et al., 1998), (Ganguly, Bandyopadhyay, Sarkar, & Chatterjee, 2006), 
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determination of ornithine decarboxylase activity (Callahan, Portal, Devereaux, & Grogl, 
1997), fluorescent dye based methods such as propidium iodide and fluorescence 
activated cell sorter (Gazanion et al., 2011), (Sereno, Alegre, Silvestre, Vergnes, & 
Ouaissi, 2005). 
Until recently, axenic promastigotes model was used to screen potential 
antileishmanial agents. However, promastigotes (sand fly stage) is widely different from 
the relevant stage amastigotes (host stage) in terms of ecology and metabolism of the 
parasite’s stages. In addition, promastigotes culture is maintained at 24-27 °C, this 
temperature is opposed to the in vivo temperature (37 °C) hence; the activity of the 
compounds may have different effects. Therefore, data obtained from screened 
compounds against axenic promastigotes may not be reflected in axenic amastigotes, 
infected macrophage model nor animal studies (Peters, Evans, & Lanham, 1983), 
(Simon L Croft, Karin Seifert, et al., 2006). 
In vivo model can assess not only the activity of the compounds against 
Leishmania but also the rout of administration (absorption) and the ability of the 
compounds to reach the site of infection (distribution). Furthermore, determine if the 
compound acts as a pro-drug or as an immune-modulator (metabolism). It can also 
monitor the excretion of the compounds from the host body as well as giving an early 
indication of any toxicity. 
Focus of the Study 
This study aims to identify hit compounds from unstudied or understudied natural 
product and synthetic sources, with a focus on improved efficacy, selectivity, and oral 
bioavailability. We used our well-established axenic amastigote and infected 
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macrophage assays to screen thousands of natural product and synthetic compounds 
against Leishmania donovani. We also evaluated active hits against the mammalian cell 
line J774A.1 ensure parasite selectivity. We were able to identify more than 2000 
compounds with IC50 values of ≤ 1 µM against Leishmania donovani in multiple assays. 
Potent hits can be used as starting points for drug development efforts for the treatment 
of Leishmania donovani. 
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Figure 1.1: Leishmania Life Cycle 
(CDC, 2018). 
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Figure 1.2: Leishmania Species Promastigotes 
Promastigotes are motile thin elongated cells with anterior kinetoplast and posterior free 
flagellum. They range in size from 5-14µm in length by 1.5-3.5µm in width (CDC, 2018). 
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Figure 1.3: Leishmania Species Amastigotes 
Amastigotes are small round non-motile cells, measures around 2-4µm in diameter and 
has a nucleus and kinetoplast (CDC, 2018).  
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Figure 1.4: Drug Discovery Process and Timeline 
Drug discovery process from basic research to FDA approved drug and the 
approximate timeline for the process. 
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Figure 1.5: Hit to Lead Process in Drug Discovery 
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 Chapter Two: Discovery of Novel Antileishmanial Hits from Natural 
Product 
Note to reader   
Portions of this chapter have been previously published and reproduced with 
permission from (Thomas et al., 2017). Copyright (2017) American Chemical 
Society. Further permission related to the material excerpted should be directed to ACS.  
 
Abstract 
Leishmania is the causative agent of the neglected tropical disease 
leishmaniasis, which is transmitted by a bite of sand fly. Current treatments suffer from 
limitations such as toxicity, severe side effects, parasite resistance and high cost. 
Considering the current problems related to antileishmanial drugs, and the urgent need 
for alternatives, we investigated the leishmanicidal activity of unstudied natural product-
based extracts such as mangrove endophytic fungal extracts, Antarctic deep-sea coral, 
and hairy root extracts of Catharanthus roseus.  The investigation resulted in the 
identification of potent natural product–based compounds with submicromolar activity 
against Leishmania donovani. 
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Introduction 
Leishmaniasis is a devastating parasitic disease caused by an obligate 
intracellular protozoan of the genus Leishmania (Wang et al., 2010). Sand fly 
(Phlebotomine) is the only known vector that transmits the disease (Bates et al., 2015). 
An estimation of 900,000 to1 million people are infected with leishmaniasis per year and 
more than 300,000 deaths are reported annually (Kamhawi, 2017).Visceral 
leishmaniasis is the most fatal form of the disease if left untreated. Around 20 species of 
leishmania are pathogenic to humans.  
Leishmania donovani is the causative agent for visceral leishmaniasis on the 
Indian subcontinent and Africa, while Leishmania infantum causes the same form of 
disease in the Middle East, Central and South America (Sundar & Singh, 2016). 
Pentavalent antimony is the drug of choice in treating leishmaniasis. However, 
resistance to pentavalent antimony is increasing, particularly in India. Amphotericin B is 
the second choice drug used primarily when pentavalent antimonials fail to treat 
leishmaniasis in addition to Miltefosine, Pentamidine and Paromomycin (Ponte-Sucre et 
al., 2017). The mentioned drugs suffer from limitations such as; high cost, severe side 
effects, difficult administration route and emergence of resistance (Vijayakumar & Das, 
2018). Although, there are several ongoing vaccines projects against visceral 
leishmaniasis, they probably will not be available in the near future (Duthie et al., 2017).  
Therefore, new drugs are urgently needed to treat visceral leishmaniasis.  
Natural products have proven to be particularly effective in treatment of parasitic 
diseases (Annang et al., 2015). There are numerous natural products with potent 
leishmanicidal activities in the drug discovery pipeline (Singh, Mishra, Bajpai, Singh, & 
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Tiwari, 2014). Approximately, 60% of most drugs are natural product derivatives 
(Newman & Cragg, 2016). Similarly, anticancer drugs such as vinblastine and 
vincristine are isolated from the plant Catharanthus roseus, camptothecin is isolated 
from Camptotheca acuminata and paclitaxel is isolated from Taxus brevifolia. Also, the 
antimalarial drug such as Artemisinin is isolated from the plant Artemisia annua 
(Gutierrez-Rebolledo, Drier-Jonas, & Jimenez-Arellanes, 2017). Furthermore, new 
potential microbial extracts has been identified from the MEDINA natural product library 
and showed activity against kinetoplastid parasites, including Leishmania (Annang et 
al., 2015). There are few existing natural-product based drugs used to that treat 
leishmaniasis. Miltefosine, the only available oral drug to treat visceral leishmaniasis, is 
an alkylphospholipid. Parmomycin is an aminoglycoside molecule and  sitamaquine is 
an 8-aminoquinoline. Berberine also is active and is isolated from Berberis vulgaris 
(Wink, 2012). In addition, Gutierrez et al. have reported some reported plants extracts 
that exhibited activity against Leishmania major; these include dihydrocorynantheine, 
corynantheine, corynantheidine and other extracts against Leishmania donovani. Also, 
in Mexico, around 20 medicinal plants derivatives have been reported to have 
leishmanicidal activity. Pentalinonsterol was the only extract among the 20 to undergo in 
vivo evaluation (Gutierrez-Rebolledo et al., 2017).  
Octocorals belong to the Cnidarian Order Alcyonacea are prolific sources of 
bioactive natural products,(Blunt, Copp, Keyzers, Munro, & Prinsep, 2017) including 
neurotoxic venoms used to paralyze vertebrate prey (Jouiaei et al., 2015) and potent 
small molecule toxins that are most often terpenoids (Roethle & Trauner, 2008). 
Octocoral diterpenes exhibit potent environmental toxicity, including the protection of 
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coral eggs during annual spawning events, inhibit fouling by microbes and algae, 
ichthyotoxicity, and contribute to the destruction of coral reefs (Coll, 1992). Biomedical 
studies have followed such ecological observations and found many of the same 
diterpenes cytotoxic to mammalian cells, though the most notable biomedical 
advancement was the introduction of the diterpene pseudopterosin for commercial use 
in anti-inflammatory and wound healing applications.(Martins, Vieira, Gaspar, & Santos, 
2014) 
     Octocorals range in distribution from shallow water coral reefs to the depths of 
the abyssal plane. Shallow water species dominate the alcyonaceans with nearly 4000 
species described in the World Record of Marine Species (WoRMS) 
database("WoRMS, World Register of Marine Species," 2017) compared to just over 
600 (15%) species that are recorded in the Deep Sea Octocorals Online database 
(Mainieri et al., 2015). Natural product reports from the two groups indicates the deep 
water species are less studied: roughly 750 alcyonacean compounds are cataloged in 
MarinLit, (Bernasconi et al., 2015) but only 28 (3.5%) compounds have been described 
from 12 deep water species (Iken & Baker, 2003; Skropeta, 2008; Skropeta & Wei, 
2014; von Salm et al., 2014). The difficulty of accessing deep sea habitats has clearly 
hampered research of species hiding there, yet bioactivity profiles of, for example, 
shagenes(von Salm et al., 2014) and cristaxenicin A (Ishigami et al., 2012) suggest the 
deep water species are an understudied drug discovery resource (Thomas et al., 2017). 
Although most drug discovery studies have focused on terrestrial plants as a 
natural product source when searching for active molecules to treat diseases, the 
search for novel bioactive agents from marine organisms has increased in recent years. 
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In 2004, Ziconotide was the first marine based drug to be approved in the United States 
for the treatment of back injuries and chronic pain (Molinski, Dalisay, Lievens, & 
Saludes, 2009). Over the years, marine algae have been used as anti-inflammatory, 
analgesic, antibacterial, antiviral, anti protozoans and anticancer drugs. In recent 
studies, marine algae showed antileishmanial activity, which provided potential lead for 
antileishmanial drug discovery (Tchokouaha Yamthe et al., 2017). However, the 
translation of potential drug candidates into usable leishmaniasis treatment has been a 
challenge in drug discovery projects (Zulfiqar et al., 2017). Also, finding active 
compounds from natural product crude extracts is time consuming and expensive. 
Therefore, it is very important to use an effective high throughput screening assays to 
ensure the selection of extracts with desirable pharmacological properties to undergo 
further development (Annang et al., 2015). 
In this study we assessed natural product extracts and pure compounds from a 
variety of sources to identify new starting points for antileishmanial drug discovery. 
Materials and Methods 
Mangrove Endophytic Fungal Extracts 
As part of research collaboration with Dr. Bill Baker, his team at the University of 
South Florida has collected, cultured and extracted mangrove endophytic fungi. Of 
these, 5,664 extracts have been generated for this study and were prepared in 96- well 
plates. These extracts have been tested in Leishmania donovani axenic amastigotes 
drug sensitivity assay, cytotoxicity assay and infected macrophage drug sensitivity 
assay. A top 100 list was generated according to the activity of these extracts in the 
infected macrophage drug sensitivity assay (< 1 µg/ml) and their selectivity over J774 
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macrophages (selectivity index> 50). A selectivity index is calculated by dividing the 
cytotoxicity IC50 by the infected macrophage IC50. The top 100 extracts were then 
retested in the infected macrophage model to confirm their activity. From these data a 
top 40 list was generated from the retested extracts results according to the same 
criteria used in selecting the top 100 extracts. Then the top 10 extracts from the list 
were scaled up and tested in the infected macrophage model. From these data one 
fungal isolate was selected and scaled up and produced pure compounds that were 
tested in the infected macrophage model and cytotoxicity model as well. 
Antarctic Deep sea Coral; Keikipukalides and Furanocembrane Diterpenes 
 The Baker group collected the deep water alcyonacean Plumarella delicatissima 
from the ‘Plateau of Fascination’, approximately 240 km NE of Stanley, Falkland Islands 
(Islas Malvinas), in the Southern Ocean. While Plumarella sp. from the northwest Pacific 
Ocean near the Kuril Islands was reported to produce the diterpene plumarellide, 
(Stonik, Kapustina, Kalinovsky, Dmitrenok, & Grebnev, 2002) a rearranged 
furanocembranoid, the Southern Ocean species P. delicatissima has yielded five new 
furanocembranoid diterpenes, keikipukalide A-E. The pukalides were originally isolated 
from a Hawaiian soft coral collected near the popular tourist attraction known as the 
Blow Hole (Missakian et al., Tetrahedron 1975, 31, 2513). Puka is the Hawaiian word 
for coral. We use the Hawaiian word for child, keiki, to distinguish our pukalide 
derivatives. (1-5), along with the known diterpene pukalide aldehyde (Abramson et al., 
1991) (6) and norditerpenoid ineleganolide (Duh, Wang, Chia, & Chiang, 1999) (7) 
(Figure 2.2). All seven compounds have been tested in Leishmania donovani axenic 
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amastigotes drug sensitivity assay, cytotoxicity assay and infected macrophage drug 
sensitivity assay (Thomas et al., 2017).  
Catharanthus roseus Hairy Root Extracts 
 Seven C. roseus hairy root extracts have been tested against Leishmania 
donovani and cytotoxicity as part of collaboration with Dr. Carolyn W.T. Lee-Parsons at 
Northeastern University. Her group prepared the extracts using different growth cycle 
and conditions to provide crude extracts to be tested in Leishmania bioassays.  
Macrophage Media Preparation and Culture 
J774A.1 macrophages (ATCC, Manassas, VA) were cultured in a vented 75 cm2 
tissue culture flask using RPMI 1640 (Gibco), 1% Penicillin-Streptomycin (Gibco, 10,000 
u/ml), 10% 24 hour heat inactivated fetal bovine serum (Gibco) at a pH of 7.2. Twenty 
five ml of fresh media were added to the flasks 3 times per week and cells were serially 
passaged biweekly.  
Axenic Amastigotes Media Preparation and Culture 
L. donovani axenic amastigotes MHOM/SD/75/1246/130/ Khartoum (WR378) laboratory 
cell lines were cultured in a non-vented 25 cm2 tissue culture flask (Coning, Lowell, MA) 
using RPMI 1640 (Gibco) with 5.86 g/L MES (Sigma-Aldrich, St Louis, MO), 7.5 g/L 
Hepes (Invitrogen Corp., Carlsbad, CA), 2 g/L sodium bicarbonate (Fisher Scientific, 
Pittsburg, PA), 100 µM Xanthine (Sigma-Aldrich, St Louis, MO), 10 mg/L Hemin (Sigma-
Aldrich, St Louis, MO), 40 mg/L Tween-80 (Sigma-Aldrich, St Louis, MO), 5 g/L Trypton-
Peptone (BD Bioscience, Sparks, MD), 1 % Penicillin- Streptomycin (Gibco, 10,000 
u/ml), and 20 % 24 hours heat-inactivated FBS (Gibco). Media was set at a pH of 5.5.  
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L. donovani axenic amastigotes were cultured 1:5 three times per week and incubated 
at 37oC. 
Leishmania donovani Axenic Amastigotes Drug Sensitivity Assay 
Compounds were tested against Leishmania donovani axenic amastigotes 
(MHOM/SD/75/1246/130) using the CellTiter 96 AQueous one-solution cell proliferation 
assay (Promega, Madison, WI). In a 96 well drug plate (Costar, Assay Plate, 96 well 
with low Evaporation Lid, Flat Bottom, None-Treated, #3370) compounds were diluted 
in a series of 6 2-fold dilutions in media to produce a concentration range from 200µg/ml 
to 6.25µg/ml. Ten µL from each well was transferred to another 96 well plate (Costar, 
Assay Plate, 96 well with low Evaporation Lid, Flat Bottom, Tissue culture Treated, # 
3628) and then 90 µL of parasites in media in a 66,000 cell per well concentration was 
added to produce a final concentration range from 20µg/ml to 625ng/ml.  The plates 
were then incubated at 37oC for 72 hours. Twenty µL of MTS {3-(4,5-dimethylthiazol-2-
yl)-5(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium},(Promega, Madison, 
WI) solution was added to each well and incubated for an additional 4 hours. A Spectra 
Max M2e (Molecular Devices, Sunnyvale, Ca) was used to measure optical density (OD) 
at 490nm. Non-linear regression via Trifox software was used to determine IC50 values.  
Cytotoxicity Assay 
Compounds were tested against J774.A1 macrophages using the CellTiter 96 AQueous 
one-solution cell proliferation assay (Promega, Madison, WI). In a 96 well drug plate 
(Costar, Assay Plate, 96 well with low Evaporation Lid, Flat Bottom, None-Treated, 
#3370) compounds were diluted in a series of 6 2-fold dilutions in media to produce a 
concentration range from 500µg/ml to 15.625µg/ml. Ten µL from each well was 
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transferred to another 96 well plate (Costar, Assay Plate, 96 well with low Evaporation 
Lid, Flat Bottom, Tissue culture Treated, # 3628) and 90µL of macrophages in media in 
a 50,000 cell per well concentration was added to produce a final concentration range 
from 50µg/ml to 1.562 µg/ml. The plates were then incubated at 37oC, 5% Co2 for 72 
hours. Twenty µL of MTS {3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-
sulphophenyl)-2H-tetrazolium} (Promega, Madison, WI) solution was added to each well 
and incubated for an additional 4 hours. A Spectra Max M2e (molecular Devices, 
Sunnyvale, Ca) was used to measure optical density (OD) at 490nm. Non-linear 
regression via Trifox software was used to determine IC50 values.  
Infected Macrophage Drug Sensitivity Assay 
In a 384 well assay plate (CellCarrier-384 Black, Optically Clear Bottom, Tissue 
Culture Treated, Sterile, #6007550), 2000 J774A.1 macrophages were seeded and 
incubated for at least an hour to allow adherence. The plate was then washed with pre-
warmed media to remove the unadhered cells. L. donovani axenic amastigotes were 
added to the plate in a ratio of 10:1 and incubated at 37 oC, 5% CO2 for 24 hours. The 
excess extracellular amastigotes were then washed away using pre-warmed media. 
Compounds were prepared in a 384-drug plate (Thermo Scientific™ Nunc™ 384-Well 
Clear Polystyrene Plates with Non /treated Surfaces, #242757) with a starting 
concentration of 10 µg/ml and serially diluted in a 1:2 ratio. Drugs were then added to 
the assay plate and incubated at 37 oC, 5% CO2 for 72 hours. After that, drugs were 
removed from the plate and the adhered cells were fixed with 2% paraformaldehyde 
(Alfa Aesar™ Paraformaldehyde, 16% w/v aq. soln., methanol free, #30525-89-4) and 
incubated for 15 minutes at room temperature. Fixative was then removed and cells 
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were stained with 5 µM Draq5 (Thermo Scientific DRAQ5 fluorescent probe, DNA stain, 
#62251) and incubated for 5 minutes at room temperature. Stain was removed and 
fresh media was added to the plate. High content fluorescent imaging (Perkin Elmer 
Operetta) was used to capture images used to perform cell counts. Harmony software 
calculated the number of amastigotes per 500 macrophages in each well and used 
these counts to generate IC50 values. 
In all three assays, Miltefosine was used as a negative growth control drug and culture 
media was used as a positive growth control. 
Results and Discussion 
Natural products are well known as a rich source for lead compounds in drug 
development (Kobayashi, 2016). Not long ago, most drug discovery projects that relied 
on natural products resources focused on terrestrial plants when searching for 
antiparasitic agents with potent activity (Carvalho et al., 2017). Apparently, the interest 
in studying marine organisms as potential source for lead bioactive materials has 
elevated recently (Molinski et al., 2009). Additionally, Catharanthus roseus plant is one 
of the most broadly studied plants for medicinal use (Zhu, Zeng, Sun, & Chen, 2014). C. 
roseus leaves extracts have been reported to show activity against Plasmodium 
falciparum (Ponarulselvam et al., 2012). 
In an effort to discover new antileishmanial compounds from natural products, 
several bioactive molecules were isolated from mangrove endophytic fungal extracts 
and Antarctic deep-sea coral (keikipukalides and furanocembrane diterpenes) with 
submicromolar activity against Leishmania donovani infected macrophage assay. We 
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also investigated the antileishmanial activity in some terrestrial plant extracts such as 
Catharanthus roseus 
Mangrove Endophytic Fungal Extracts 
A total of 5,664 extracts were screened in L. donovani axenic amastigote drug 
sensitivity assay and cytotoxicity assay; of these, 1193 showed activity with an IC50 less 
than 20 µg/ml. From this group 797 of 1193 were non toxic with an IC50 greater than 50 
µg/ml against J774 macrophages (Figure 2.1). A total of 2,140 extracts have been 
tested in infected macrophage drug sensitivity assay and 1564 extracts showed activity 
with an IC50 less than 10 µg/ml (Figure 2.2). 
A list of top 100 extracts was generated according to the activity of the infected 
macrophage drug sensitivity assay results with an IC50 of <0.5 µg/ml and a selectivity 
index greater than 50. The top 100 active extracts were retested in the infected 
macrophage drug sensitivity assay and showed a 90% hit confirmation rate. A top 40 list 
was then generated from the reconfirmation list according to the IC50 value < 0.5 µg/ml 
and a selectivity index >50. The top 10 extracts were selected, scaled up and retested 
in the infected macrophage model, which demonstrated a 60% re-hit rate. From these 
top 10 list, one fungal Isolate was selected, scaled up and produced a number of pure 
compounds, Phomopsichromin A, Phomopsichromin B, Phomopsichromin C, 
Phomopsichromin D, Phomopsichromin E. These pure compounds were tested in the 
infected macrophage model and cytotoxicity model. Phomopsichromin C was the most 
active compounds with an IC50 = 0.67 µM and a selectivity index = 74.6 (Table 2.1), 
(Figure 2.3). 
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Antarctic Deep sea Coral; Keikipukalides and Furanocembrane Diterpenes 
The seven terpenoids isolated from Plumarella delicatissima were evaluated 
against a number of infectious disease targets. Leishmania donovani was quite 
sensitive, displaying an IC50 of 1.9-11.9 µM for compounds 2-7 (Table 2.2), (Figure 2.4) 
in the infected macrophage assay, compared to the IC50 of 6.2 µM for miltefosine, a 
drug currently used for the treatment of leishmaniasis. No mammalian cytotoxicity was 
detected in the compounds below 50 µM. However, testing in a number of other 
infectious diseases, including, Naegleria fowleri, the ESKAPE (Rice, 2008) panel of 
drug resistant bacteria and Clostridium difficile, found none of these pathogens 
susceptible to the compounds (data not shown). Although this seeming specificity for L. 
donovani is promising for this scaffold, most of these compounds contain the neurotoxic 
pharmacophore of lophotoxin,(Abramson et al., 1991) which may prove to be a liability. 
Plumarella belongs in the family Primnoidae (suborder Calcaxonia), while nearly all 
similar furanocembranoid scaffolds have been reported from the Alcyoniidae or 
Gorgoniidae (suborders Alcyoniina or Holaxonia, respectively). However, briarane 
diterpenes have been isolated from Ellisellidae, which, like the Primnoidae, is in the 
suborder Calcaxonia. Octocoral phylogeny is in a state of flux after the integration of 
molecular data, and further investigations into the origin of these metabolites to possibly 
define a pattern between this and other coral genera could give chemotaxonomic or 
evolutionary insight into octocoral species around the globe (Thomas et al., 2018).  
Catharanthus roseus Hairy Root Extracts  
Seven crude extracts of Catharanthus roseus Hairy Root have been tested in 
Leishmania donovani axenic amastigotes drug sensitivity assay and cytotoxicity assay. 
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All seven extracts showed no activity when tested at the highest concentration in the 
axenic amastigote model with an IC50 of >20 µg/ml and no sign of cytotoxicity with an 
IC50 of >50 µg/ml. Interestingly, all 7 extracts displayed activity in the infected 
macrophage model with an IC50 ranged between 2.42 µg/ml to 5.32 µg/ml (Table 2.3). 
To our knowledge, no leishmanicidal activity of Catharanthus roseus hairy root extracts 
has been reported previously.  
By screening these natural products against Leishmania donovani, we were able 
to identify a number of novel hits with excellent antileishmanial activity. Further 
investigation and lead optimization are needed to determine if lead compounds have 
chemical and physical properties that would make them orally active drugs. Therefore, 
increase their possibility to undergo clinical trials with a good chance of reaching the 
market as a drug for leishmaniasis.  
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Figure 2.1: Mangrove Endophytic Fungi Extracts Activity in L. donovani Axenic 
Amastigotes Drug Sensitivity Assay and Cytotoxicity Assay 
Total number of tested mangrove endophytic fungi extracts in L. donovani axenic 
amastigotes drug sensitivity assay and cytotoxicity assay, number of active extracts with 
an IC50 less than 20 µg/ml and the number active not toxic extracts with an IC50 >50 
µg/ml in the cytotoxicity assay. 
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Figure 2.2: Mangrove Endophytic Fungi Extracts Activity in L. donovani Infected 
Macrophage Assay 
Total number of tested mangrove endophytic fungi extracts in the infected macrophage 
drug sensitivity assay and the number of active extracts with an IC50 <10 µg/ml. 
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Table 2.1: Mangrove Endophytic Fungi Pure Compounds Activity (IC50 µM) 
Sample Infected Macrophage Cytotoxicity Selectivity Index 
Phomopsichromin A 3 >50 16.6 
Phomopsichromin B 1.9 >50 26.3 
Phomopsichromin C 0.67 >50 74.6 
Phomopsichromin D >10 >50 5 
Phomopsichromin E 0.80 >50 62.5 
 
The > symbol indicates the sample was inactive at the highest concentration tested. 
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Figure 2.3: Structure of Phomopsichromin C 
Infected macrophage IC50 = 0.67 µM and a selectivity index = 74.6. 
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Table 2.2: Bioactivity of Plumarella Terpenes (IC50 µM) 
Sample Infected Macrophage A549 Cytotoxicity Selectivity Index 
Keikipukalide -A >28.1 >50 5 
Keikipukalide -B 8.5 >50 5.88 
-Keikipukalide -C 8.8 >50 5.68 
Keikipukalide -D 11.9 >50 5 
Keikipukalide -E 8.8 >50 5.68 
Pukalide aldehyde 1.9 >50 26.3 
Ineleganolide 4.4 >50 11.3 
Miltefosine (control) 6.2 Not determined Not determined 
 
The > symbol indicates the sample was inactive at the highest concentration tested 
(Thomas et al., 2018).  
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Figure 2.4: Chemical structures of Plumarella Terpenes 
Five new furanocembranoid diterpenes, keikipukalide A-E (1-5), known diterpene 
pukalide aldehyde (6) and norditerpenoid ineleganolide (7), (Thomas et al., 2018). 
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Table 2.3: Catharanthus roseus Hairy Root Extracts Activity (IC50 µg/ml) 
Sample Axenic 
Amastigotes 
J774 
Cytotoxicity 
Infected 
Macrophage 
Infected 
Macrophage 
Selectivity Index 
1 >20 >50 2.53 19 
2 >20 >50 3.04 16 
3 >20 >50 5.32 9 
4 >20 >50 3.65 13 
5 >20 >50 2.42 20 
6 >20 >50 5.13 9 
7 >20 >50 4.8 10 
Miltefosine 1.5 >50 2.56 20 
 
The > symbol indicates the sample was inactive at the highest concentration tested. 
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 Chapter Three: Discovery of Potential Antileishmanial Synthetic 
Compounds 
Note to reader 
 Portions of this chapter have been previously published and reproduced with 
permission from (Giulianotti et al., 2017). Copyright (2017) American Chemical 
Society. Further permission related to the material excerpted should be directed to ACS.  
 Portions of this chapter have been previously published and reproduced with 
permission from (Kanwar et al., 2017). Copyright (2017) American Chemical 
Society. Further permission related to the material excerpted should be directed to ACS. 
Portions of this chapter have been previously published and reproduced with 
permission from (McQueen et al., 2017). Copyright (2017) Elsevier. Further permission 
related to the material excerpted should be directed to Elsevier. 
Abstract 
Leishmaniasis is a major neglected tropical disease caused by Leishmania 
species parasites. Visceral leishmaniasis is the most devastating form of the disease 
and can be fatal if left untreated. Limitations to current treatments such as the 
development of resistance by the parasite against drugs, high toxicity, difficult 
administration route and limited availability in some endemic areas are major concerns. 
Therefore, the search for new drugs is urgently needed to treat this disease. Thus, a 
total of 46,011 synthetic compounds with different classes of molecules were 
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synthesized by different collaborators and screened in multiple Leishmania donovani 
assays in our lab. In this project, we were able to identify new hits from several different 
classes of compounds by using phenotypic screening assays and high content imaging 
screening assay. The following represent the most potent antileishmanial compound in 
each class in the infected macrophage model exhibiting limited toxicity toward the host 
macrophages; Monoamidines DB2381 (IC50= 0.15 µM, SI= 181), Thiazoles KP-16 
(IC50= 0.19 µg/ml, SI= 247), Quinazolines QUI1209 (IC50= 0.27 µM, SI= 85), 
Pyrazolo[3,4-c ]pyrimidines SNX2112 compound 18 (IC50= 1.06 µM, SI= 47), 
Monoguanidines 64 (IC50= 1.13 µM, SI= 23). These potent compounds were 
significantly more active than the currently used oral drug, miltefosine.  
Introduction 
Visceral leishmaniasis is the severe form of the neglected tropical disease 
leishmaniasis caused by Leishmania donovani parasite (Ozbilgin et al., 2017). 
Transmission of the disease can occur by a bite of the Phlebotomine sand fly. The 
infective stage promastigote is injected into the host body during a blood meal and 
transforms into the intracellular pathogenic tissue stage amastigotes (Tomassone et al., 
2018).  
The treatment of visceral leishmaniasis is very challenging due to limited 
chemotherapy options. Furthermore, these drugs suffered from severe side effects, 
toxicity, high cost, limited availability, difficult administration route, long treatment 
duration and elevated parasite resistance to administered drugs (Ortiz et al., 2017). 
Although there are several reports and clinical trials for potential vaccines against 
visceral leishmaniasis, an effective vaccine is not available to date (Kusakisako et al., 
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2018). These issues increased the complexity of the treatment of this disease. 
Therefore, additional new drugs with improved properties to overcome the current 
problems are vitally needed. Several reported studies addressed the urgent need for 
new chemotherapies and identified novel antileishmanial hits.  
Wang et al. identified a new class of molecules (AIAs, arylimidamides containing 
2 pyridylimidamide terminal groups) with submicromolar activity against Leishmania 
donovani axenic amastigote assay and infected macrophage assay (Wang et al., 2010). 
The two novel orally bioavailable AIA’s molecules DB745 and DB766 were exceptionally 
active in the Leishmania donovani infected macrophage assay (IC50 less than 0.12 µM). 
Both compounds were also evaluated in vivo for efficacy and inhibited parasitemia level 
in Leishmania donovani infected hamsters and mice (Wang et al., 2010). Mono-AIA 
(containing a single pyridylimidamide terminal group) was also identified as a new class 
of lead compounds for drug development against Leishmania donovani (Zhu et al., 
2016).  
On the other hand, quinazoline derivatives were also reported for their promising 
antileishmanial activity. Quinazoline analogs are characterized by their ease of 
synthesis and suitable physiochemical properties (Sahu, Kumar, & Agrawal, 2017). 
These features made quinazoline an attractive class of candidate molecules for 
antileishmanial drug development. Agarwal et al. designed and synthesized 4-
(Substituted-benzylidine)-2-substituted-5,6-dihydrobenzo[h]quinazoline and 4-
(substituted-benzylidine)-2-substituted-3, 4, 5, 6-tetrahydrobenzo[h]quinazoline from 2-
(substituted-benzylidine)tetralone-1 and several substituted guanidine sulfates. The 2 
compounds profound promising antileishmanial hit against Leishmania donovani 
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(Agarwal, Sharma, Shakya, & Gupta, 2009). In addition, a series of N2,N4 -disubstituted 
quinazoline-2,4-diamines are considered promising lead for the development of 
antileishmanial agent due to their ease of synthesis and desirable physiochemical 
properties. The potent compound (23) from this series demonstrated efficacy in the 
murine model of visceral leishmaniasis with 37% inhibition of liver parasitemia when 
given at 15 mg/kg for 5 consecutive days (Van Horn et al., 2014). It is believed that 
quinazolines inhibit dihydrofolate reductase (Gilbert, 2002). Van Horn et al investigated 
the possibility of this mechanism of action and found that quinazolines were less active 
in the presence of folic acid, which supported the hypothesis of previous studies (Van 
Horn et al., 2014).  
Moreover, Hsp90 inhibitors displayed activity against some protozoan parasites 
including Leishmania (Varela, Mollinedo-Gajate, Muro, & Mollinedo, 2014). Hsp90 is a 
protein that overexpressed in stressed cells (Taipale, Jarosz, & Lindquist, 2010).  
Another class of compounds such as azoles was also investigated as an 
antileishmanial agent. Fexinidazole (nitro-imidazole) and PA-824 (4-nitroimidazo-
oxazine) are in phase II clinical trial with promising antileishmanial results. Fexinidazole 
is a treatment for human African Trypanosome and believed to act as a prodrug that 
releases cytotoxic metabolites damaging DNA, lipid, and protein. In contrast, PA-824 
has antibacterial properties against M. tuberculosis. PA-824 displayed high efficacy 
when tested in a murine model of visceral leishmaniasis (Sundar & Singh, 2016).  
In this study we evaluated synthetic compounds from a variety of different 
chemical scaffolds to identify new hits and to begin structure activity studies to optimize 
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the hits into lead compounds suitable for further development as new drugs for visceral 
leishmaniasis. 
Materials and Methods 
Macrophage Media Preparation and Culture 
J774A.1 macrophages (ATCC, Manassas, VA) were cultured in a vented 75 cm2 
tissue culture flask using RPMI 1640 (Gibco), 1% Penicillin-Streptomycin (Gibco, 10,000 
u/ml), 10% 24 hour heat inactivated fetal bovine serum (Gibco) at a pH of 7.2. Twenty-
five ml of fresh media were added to the flasks 3 times per week and cells were serially 
passaged biweekly.  
Axenic Amastigotes Media Preparation and Culture 
L. donovani axenic amastigotes MHOM/SD/75/1246/130/ Khartoum (WR378) 
laboratory cell lines were cultured in a non-vented 25 cm2 tissue culture flask (Coning, 
Lowell, MA) using RPMI 1640 (Gibco) with 5.86 g/L MES (Sigma-Aldrich, St Louis, MO), 
7.5 g/L Hepes (Invitrogen Corp., Carlsbad, CA), 2 g/L sodium bicarbonate (Fisher 
Scientific, Pittsburg, PA), 100 µM Xanthine (Sigma-Aldrich, St Louis, MO), 10 mg/L 
Hemin (Sigma-Aldrich, St Louis, MO), 40 mg/L Tween-80 (Sigma-Aldrich, St Louis, 
MO), 5 g/L Trypton-Peptone (BD Bioscience, Sparks, MD), 1 % Penicillin- Streptomycin 
(Gibco, 10,000 u/ml), and 20 % 24 hours heat-inactivated FBS (Gibco). Media was set 
at a pH of 5.5.  L. donovani axenic amastigotes were cultured 1:5 three times per week 
and incubated at 37oC. 
Leishmania donovani Axenic Amastigotes Drug Sensitivity Assay 
Compounds were tested against Leishmania donovani axenic amastigotes 
(MHOM/SD/75/1246/130) using the CellTiter 96 AQueous one-solution cell proliferation 
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assay (Promega, Madison, WI). In a 96 well drug plate (Costar, Assay Plate, 96 well 
with low Evaporation Lid, Flat Bottom, None-Treated, #3370) compounds were diluted 
in a series of 6 2-fold dilutions in media to produce a concentration range from 200µg/ml 
to 6.25µg/ml. Ten µL from each well was transferred to another 96 well plate (Costar, 
Assay Plate, 96 well with low Evaporation Lid, Flat Bottom, Tissue culture Treated, # 
3628) and then 90µL of parasites in media in a 66,000 cell per well concentration was 
added to produce a final concentration range from 20µg/ml to 625ng/ml.  The plates 
were then incubated at 37oC for 72 hours. Twenty µL of MTS {3-(4,5-dimethylthiazol-2-
yl)-5(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium},(Promega, Madison, 
WI) solution was added to each well and incubated for an additional 4 hours. A Spectra 
Max M2e (Molecular Devices, Sunnyvale, Ca) was used to measure optical density (OD) 
at 490nm. Non-linear regression via Trifox software was used to determine IC50 values.  
Cytotoxicity Assay 
Compounds were tested against J774.A1 macrophages using the CellTiter 96 
AQueous one-solution cell proliferation assay (Promega, Madison, WI). In a 96 well 
drug plate (Costar, Assay Plate, 96 well with low Evaporation Lid, Flat Bottom, None-
Treated, #3370) compounds were diluted in a series of 6 2-fold dilutions in media to 
produce a concentration range from 500µg/ml to 15.625µg/ml. Ten µL from each well 
was transferred to another 96 well plate (Costar, Assay Plate, 96 well with low 
Evaporation Lid, Flat Bottom, Tissue culture Treated, # 3628) and 90µL of macrophages 
in media in a 50,000 cell per well concentration was added to produce a final 
concentration range from 50µg/ml to 1.562 µg/ml. The plates were then incubated at 
37oC, 5% Co2 for 72 hours. Twenty µL of MTS {3-(4,5-dimethylthiazol-2-yl)-5(3-
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carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium} (Promega, Madison, WI) 
solution was added to each well and incubated for an additional 4 hours. A Spectra Max 
M2e (molecular Devices, Sunnyvale, Ca) was used to measure optical density (OD) at 
490nm. Non-linear regression via Trifox software was used to determine IC50 values.  
Infected Macrophage Drug Sensitivity Assay 
In a 384 well assay plate (CellCarrier-384 Black, Optically Clear Bottom, Tissue 
Culture Treated, Sterile, #6007550), 2000 J774A.1 macrophages were seeded and 
incubated for at least an hour to allow adherence. The plate was then washed with pre-
warmed media to remove the unadhered cells. L. donovani axenic amastigotes were 
added to the plate in a ratio of 10:1 and incubated at 37 oC, 5% CO2 for 24 hours. The 
excess extracellular amastigotes were then washed away using pre-warmed media. 
Compounds were prepared in a 384-drug plate (Thermo Scientific™ Nunc™ 384-Well 
Clear Polystyrene Plates with Non /treated Surfaces, #242757) with a starting 
concentration of 10 µg/ml and serially diluted in a 1:2 ratio. Drugs were then added to 
the assay plate and incubated at 37 oC, 5% CO2 for 72 hours. After that, drugs were 
removed from the plate and the adhered cells were fixed with 2% paraformaldehyde 
(Alfa Aesar™ Paraformaldehyde, 16% w/v aq. soln., methanol free, #30525-89-4) and 
incubated for 15 minutes at room temperature. Fixative was then removed and cells 
were stained with 5 µM Draq5 (Thermo Scientific DRAQ5 fluorescent probe, DNA stain, 
#62251) and incubated for 5 minutes at room temperature. Stain was removed and 
fresh media was added to the plate. High content fluorescent imaging (Perkin Elmer 
Operetta) was used to capture images used to perform cell counts. Harmony software 
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calculated the number of amastigotes per 500 macrophages in each well and used 
these counts to generate IC50 values. 
In all three assays, Miltefosine was used as a negative growth control drug and 
culture media was used as a positive growth control. 
Guanidines 
Giulianotti et al have previously reported on the use of mixture-based libraries to 
rapidly identify and prioritize active scaffolds (Rideout et al., 2011; Wu et al., 2013).  
Using this approach, we evaluated a scaffold-ranking library containing >6,000,000 
compounds in a L. donovani axenic amastigote assay as well as a high-content imaging 
screen utilizing macrophages infected with L. donovani amastigotes. As previously 
described in detail (Rideout et al., 2011; Wu et al., 2013) a scaffold-ranking library is a 
collection of mixture samples where each mixture sample contains only compounds with 
the same core scaffold, and therefore all the compounds in a given mixture are close 
structural analogs. Additionally, each compound in a specific mixture sample is 
represented in approximately equal molar concentration. From this initial screen, the 
bis-cyclic guanidine scaffold-ranking sample Lib1 demonstrated potency in both of the 
aforementioned leishmaniasis assays with no sign of cytotoxicity in an uninfected 
macrophage counter screen. A positional scanning library was then screened in order to 
develop an SAR profile around the core bis-cyclic guanidine scaffold. From this 
analysis, 27 individual compounds were selected as good candidates to validate the 
profile.  
Upon confirmation of the SAR trends with the individual compounds, a lead 
optimization campaign was undertaken to further explore the SAR profile around the 
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scaffold. These efforts resulted in the discovery of several new compounds possessing 
sub-micromolar IC50s in the L. donovani infected macrophage assay. Among the hits is 
a monocyclic guanidine compound, 64 (Giulianotti et al., 2017).  
SNX2112 Analogues 
We recently found that SNX2112, 1 (Figure 3.1), (Chandarlapaty et al., 2008) showed 
potent activity in a high throughput axenic L. donovani amastigote assay (Varela et al., 
2014). This compound was previously known to have potent antitumor activity, and a 
prodrug analog SNX5422, 2 (Figure 3.2) is currently in multiple clinical trials for 
oncology indications (Reddy et al., 2013), (Infante et al., 2014). The biochemical target 
of 1 is Hsp90, a ubiquitous chaperone protein known to facilitate protein folding and one 
that is often overexpressed in stressed cells (Taipale et al., 2010), It is the putative 
target of known bioactive natural products such as radicicol (Sharma, Agatsuma, & 
Nakano, 1998), and has proven to be a viable focus for oncology drug discovery. A 
number of Hsp90 inhibitors have been investigated in human clinical trials such as 
breast cancer, colorectal cancer and hepatic cancer (Trepel, Mollapour, Giaccone, & 
Neckers, 2010). Given that Hsp90 or related orthologs have been identified not just in 
mammals but in organisms from bacteria to yeast, it seemed reasonable that it could 
therefore serve as a viable target for the development of antiprotozoal agents. Indeed, 
there have been a number of reports of Hsp90 inhibitors that also possess activity 
against protozoan parasites (Woodford et al., 2016), including Trypanosoma brucei 
(African sleeping sickness), (Meyer & Shapiro, 2013), (Giannini & Battistuzzi, 2015), 
Plasmodium falciparum (malaria) (Giannini & Battistuzzi, 2015) (Shahinas, Folefoc, & 
Pillai, 2013) and Leishmania spp. (leishmaniasis), (Varela et al., 2014). We therefore 
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sought to explore the prospects of optimizing this initial hit as a potential antileishmanial 
agent. Critical to these efforts would be to ensure that any analogs would demonstrate 
this activity without demonstrating significant cytotoxicity, which would mitigate the 
potential usefulness of these agents as selective antileishmanial agents. 
 The initial discovery of 1 focused primarily on modifications to the anthranilamide 
portion in an attempt to optimize for pharmacokinetic parameters (Huang et al., 2009). 
This decision was based in part on docking studies that suggested the anthranilamide 
contributed to two of the three critical hydrogen bonds with the target and the apparent 
solvent exposure of the amine substituent. Notably, little attention was paid to the 
geminal methyl substituents other than to note that their presence was essential for 
activity. Given that their presence was primarily a result of the use of dimedone as the 
starting material for the synthesis of the initial lead series, we felt that this portion 
warranted additional consideration. 
In order to confirm the initial hit compound, we prepared compounds 9 – 11 
(Figure 3.3). We eschewed the CF3 substituent in the hopes of restricting the 
cytotoxicity in this series (Huang et al., 2009). We also prepared quinazoline 11, which 
restricted the majority of the rotatable bonds to facilitate docking studies. Since this 
compound also displayed activity in our initial assay, we felt that it was an excellent 
candidate for docking into the active site of Hsp90. Using publicly available coordinates 
(3D0B) (Barta et al., 2008) for a co-crystal in AutoDock 1.5.6 (Trott & Olson, 2010) 
suggested that 11 would fit well into the active site, and that the geminal methyl 
substituents would access a hydrophobic pocket that might be exploited for additional 
activity or selectivity (Figure 3.4). We therefore set out to prepare analogs that would 
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allow us to introduce diversity late in the synthesis in order to evaluate their activity. We 
also considered the typical Lipinski/physicochemical parameters for each of these 
analogs in order to maximize the likelihood that any active compounds would have a 
reasonable chance at achieving acceptable oral bioavailability (Veber et al., 2002). 
We envisioned that an appropriately adorned pyrazolo[3,4-c]pyridine core would 
serve as a suitable replacement for the initial scaffold such that the amine would provide 
a versatile handle for the installation of functionality that could probe this pocket. 
Toward that end, alkylation of the ethyl ester of N- benzylglycine with chloroacetone 
followed by tert-butoxide promoted cyclization gave cyclic β-diketone 13 (Figure 3.5) 
(Ziegler & Bennett, 1973). C-Acylation of this material proved more difficult than we 
anticipated, but the initial mixture of C- and O-acylated compounds could be converted 
to the desired 14 by cyanide equilibration. Condensation of this material with the 
arylhydrazine gave the requisite bromonitrile 15, which was able to undergo Buchwald-
Hartwig amination and nitrile hydration to afford tertiary amine 16. The benzyl group 
could be reductively removed under acidic conditions to give 17, which served as a 
viable intermediate for the generation of substituted analogs. Acylation of 17 was able to 
be conducted with a series of readily available acid chlorides (Figure 3.5). Similarly, 
sulfonylation was easily achieved. Urea formation was conducted through the auspices 
of a benzyle carbamate, which could be debenzylated to give the parent 26. 
In addition to evaluating these analogs in the initial high throughput axenic 
amastigote assay, we also investigated their activity in a high content screening (HCS) 
infected macrophage assay using transformed J774 murine macrophages that also 
allows us to evaluate cytotoxicity and ensure that the activity we see is not a general 
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cytotoxic phenomenon (Siqueira-Neto et al., 2012). Since the ultimate goal of this work 
is to identify a compound that not only demonstrates antileishmanial activity but also 
has the potential to be orally bioavailable, we considered the typical Lipinski “rule of 5” 
parameters for each of the compounds evaluated. Furthermore, we also considered 
other factors such as the number of rotatable bonds and the total polar surface area 
(tPSA) (Veber et al., 2002). These evaluations were completed using the DruLiTo drug 
likeness tool open source calculator (Kanwar et al., 2017). 
Mono-amidine Analogues 
 Dr. David Boykin research group at Georgia State University focuses on the 
synthesis and development of molecules based on its ability to selectively bind to the 
minor groove of AT regions of DNA in order to inhibit one or more DNA dependent 
enzymes. The Boykin group has found that certain linear diamidines can attach to the 
minor groove with high affinity; therefore, they extended the design strategy of these 
molecules and evaluated their activity in multiple protozoan diseases and AIDS-related 
opportunistic diseases.  Their focus was also on developing not only active antimicrobial 
agents but also has the potential to be orally bioavailable. As of that, 38 mono-amidine 
samples were selected and evaluated in the antileishmanial axenic amastigotes and 
infected macrophage assays in our lab.  
Quinazolines  
 Quinazolines have been reported to have a significant antileishmanial activity. In 
previous work, Van Horn et al. showed a series of quinazolines as promising 
antileishmanial compounds. The efficacy of these compounds was also evaluated in a 
murine visceral leishmaniasis model (Van Horn et al., 2014). 
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Dr. Roman Manetsch research group at Northeastern University has synthesized 
a series of new quinazoline analogues. All 76 compounds were examined in the axenic 
amastigote and infected macrophage assays. Their toxicity was also assessed as 
described above. The IC50 values of all compounds were calculated and, some of them 
exhibited a submicromolar number in the infected macrophage assay with high 
selectivity index.  
Thiazole  
 Thiazole based compounds showed potent activity against Leishmania donovani 
in many reported studies. Among these reports, a series of aminothiazoles were tested 
in in vitro and showed a potent antileishmanial activity as low as IC50= 0.003 µM but had 
some issues with metabolic stability (Bhuniya et al., 2015). A series of phthalimido-
thiazole derivatives was also reported to have activity against Leishmania infantum 
(Alianca et al., 2017). 
Dr. Kirpal Bisht research group at USF synthesized and developed 19 thiazole 
analogues. Their antileishmanial activity and mammalian cytotoxicity were tested and 
the IC50 values were calculated as mentioned previously. Most of these analogues 
showed very potent submicromolar activity in both the axenic amastigotes and infected 
macrophage assays with excellent selectivity index comparable to the reference drug 
miltefosine.  
Primaquine-coumarin fluorescent probe (PQCP) 
Dr. Adonis McQueen (a former PhD student in the Kyle Lab) developed 
Primaquine-coumarin fluorescent probe (PQCP, a fluorescent-tagged primaquine) to 
discover cellular localization in Plasmodium falciparum, a human malaria parasite. 
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Primaquine (PQ) is the only known antimalarial drugs that clears dormant parasites in 
the liver and stop the transmission cycle of the parasites. We evaluated the 
antileishmanial activity of both PQCP and PQ in the Leishmania donovani axenic 
amastigote assay and assessed their cytotoxicity using J774A.1 macrophages 
(McQueen et al., 2017). 
Results and Discussion 
We have been actively engaged in drug discovery projects and collaborating with 
universities and institutes aiming for the discovery of novel antileishmanial compounds. 
Drug discovery for protozoan diseases has been improved by the use of improved 
screening assays. We used our well-established screening assays and screened 
millions of compounds against Leishmania donovani axenic amastigotes and infected 
macrophage. These compounds were provided by different drug discovery expertise in 
the field and demonstrated exceptional antileishmanial activity in multiple assays. 
Guanidines 
 We initiated our study by screening 28 of our scaffold-ranking libraries at 4 doses 
(50, 25, 5, and 2.5 µM) in an assay using axenic L. donovani amastigote strains, CR6 
and CS1 as described in Wang et al (Wang et al., 2010). Only scaffold-ranking sample 
Lib1 showed substantial activity at any of the doses tested, producing >90% inhibition 
at the 25 and 50 µM doses.  
While the axenic amastigote assay allows for a quick assessment of a sample’s 
intrinsic anti-leishmanial activity, it does have the weakness in that the effect of the host 
mammalian cell cannot be taken into account. In order to assess the anti-leishmanial 
efficacy of the scaffold-ranking samples against intracellular parasites, a high content 
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screening (HCS) assay with L. donovani infected J774 macrophages was utilized 
(Siqueira-Neto et al., 2012). In addition, a counter screen assay utilizing non-infected 
J774 macrophages was performed on the scaffold-ranking samples to assess their 
potential toxicity to the host mammalian cell. From these two assays, a selectivity index 
(SI) was calculated by dividing the IC50 obtained from the non-infected macrophage by 
the IC50 from the infected macrophage assay. From this infected macrophage screen, 
we found several scaffolds with attractive activity (sub-micromolar IC50) and selectivity 
(> 50 SI) profiles, one of which was Lib1. We thus turned our attention to exploring a 
positional scanning study on this scaffold. 
Using our previously described synthetic methods (Wang et al., 2010), (Reed, 
Coler, Mondal, Kamhawi, & Valenzuela, 2016), we screened a 110 sample array around 
Lib1 (42 carboxylic acids x 42 carboxylic acids x 26 amino acids). In this manner, we 
were able to evaluate a total of 45,864 different bis-cyclic guanidine analogs, where 
each compound was replicated in 3 different samples. The results of these screens are 
shown in (Table 3.1- 3.3). Although the libraries were evaluated at several 
concentrations, the best range of results was apparent at 5 µM, and the percent 
inhibition at this concentration is shown (Santos et al., 2013). This data allowed us to 
rank order the relative likelihood that active individual compounds contain certain 
functionalities at a given position and to begin to augur certain trends. For example, 
based on the 5 µM data, it is clear that the mixture defined with cyclohexylbutyl at the R1 
position (Table 3.1 sample Lib1.031), is more active (100%) than the one defined with 
isobutyl (0%) at the same R1 position (Table 3.1 sample Lib1.022). This implies that it is 
more likely to find active individual compounds with cyclohexylbutyl defined at R1 than 
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with isobutyl at R1. Across all three of these positions, oxygenated substituents 
dramatically reduced activity at the 5 µM dose. Also, there appears to be little 
preference for stereochemical specificity at the R2 position (Table 3.2), where 
diastereomeric mixtures (e.g. Lib1.046/Lib1.054 and Lib1.049/Lib1.057) demonstrated 
nearly identical activities. In addition to the axenic amastigote data in (Table 3.1- 3.3), 
the IC50 data from the HCS infected macrophage assay is also provided. The infected 
macrophage data does not correlate perfectly with the axenic amastigote data, which is 
consistent with what we observed in our initial scaffold-ranking studies. While both 
assays measure the ability of a sample to inhibit the growth of the amastigotes at a 
given dose, the infected macrophage assay requires the samples to penetrate the 
macrophage first in order to get to the amastigote. Regard-less, a number of the 
samples that produced sub 2.5 µM IC50 in the infected macrophage assay also 
produced a >80% response at the 5 µM dose in the axenic amastigotes assay, 
demonstrating these samples’ ability to inhibit the growth of the amastigotes in both 
assay formats. In order to confirm some of the SAR trends that were observed in the 
positional scanning library data as well as to identify individual hit compounds with 
antileishmanial activity, a set of previously synthesized bis-cyclic guanidines were 
selected for testing (Fleeman et al., 2015). The compounds were synthesized as 
previously described incorporating 3 different functionalities in each of the R1, R2 and R3 
positions resulting in 27 structural analogs (Table 4). These different functionalities, 
when incorporated into the positional scanning library, demonstrated a range of 
activities in the anti-Leishmania proliferation assays (Table 3.1- 3.3) therefore making 
them a good set to test the SAR, which is shown in (Table 3.4). In general, when 
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cyclohexylbutyl was fixed in the R1 position (Compounds 15 to 23), the compounds 
showed an increased response in the axenic amastigote assay (6 out of 9 showed > 
65% inhibition at 2.5 µM) relative to the other compounds (2 out of 18). These results 
are consistent with the data generated from the positional scanning library data (Table 
3.1) where Lib1.031 showed greater activity than Lib1.041 or Lib1.007. Of those 9 
individual compounds (15-23), the compounds where R2 was R-2-naphthylmethyl were 
the inactive analogs (18-20). Again, this is consistent with the positional scanning data 
(Table 3.2) showing that Lib1.066 was much less active than Lib1.063 or Lib1.067. 
Using these trends as well as the range of activity in the infected macrophage and 
cytotoxicity assays, we initiated lead optimization activities. To facilitate screening, each 
sample was run as single data points, with miltefosine as a control on each plate. The 
IC50 for this standard is 1.43 ± 0.20 µM, and no plates contained significant outliers for 
the control.  
 The first two candidates we selected for further exploration were 21 and 26, both 
of which showed submicromolar activity in the infected macrophage assay with 
dramatically different activities in the axenic amastigote assay. In both cases, we 
prepared a series of deletion analogs (in hopes of decreasing their lipophilicity) as well 
as inverting the stereocenter built into the initial scaffold (33 and 40, (Table 3.5). In both 
cases, this scaffold change resulted in a significant decrease in the activity. For the 
series around 21, most of the deletion compounds resulted in a significant deleterious 
effect on the infected macrophage activity, with the sole exception being 34. However, 
the good activity and SI profiles for 42 and 43 suggested that we might be able to focus 
our attention on monosubstituted analogs. Toward this end, while biphenyl compound 
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46 was not particularly active, the truncated phenethyl compound 47 showed excellent 
activity and selectivity. 
 We also pursued additional studies around compounds 6 and 8, which differed 
only about the R3 position, but showed considerable activity in the infected macrophage 
assay (Table 3.6). While we again observed some compounds with acceptable activity 
and SI profiles, we were pleased to note that monosubstituted analog 50 was quite 
potent. We therefore synthesized and analyzed some analogs around this compound. 
Desfluoro analog 55 gave an excellent profile and indicated a preference for meta-
substitution (see 54, 56 and 57). Saturation of the ring revealed that 59 was another 
analog with an excellent profile. 
 Encouraged by the identification of multiple monosubstituted analogs with 
submicromolar activity and low cytotoxicity, we wanted to determine the necessity of 
having two guanidine units. We were further struck by the prospect that the butyl 
substitution at R2 could serve as a surrogate for the scaffold linker (Figure 3.7). In this 
regard, we could consider the R1 and R3 substituents together. Toward this end, we 
synthesized a series of monoguanidine analogs with and without the butyl substituent 
(Table 3.7), which clearly showed that the butyl group improved the activity. 
Furthermore, the optimal activity of 47 was closely reflected in analog 64, which showed 
an excellent SI and was more potent in our infected macrophage assay as miltefosine, a 
clinically-used antileishmanial agent that is used as our standard. By using Torry Pines 
scaffold ranking and positional scanning libraries, we were able to identify a series of 
guanidine-based compounds that possessed potent antileishmanial activity in multiple 
assays as well as selectivity over human macrophages, demonstrating that activity is 
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unlikely to arise through simple promiscuous interactions. These compounds are 
structurally distinct from any of the currently used antileishmaniasis agents as shown in 
(Figure 3.8), and thus represent a novel opportunity for lead optimization. We were 
subsequently able to use these libraries to focus in on compounds such as 64 that 
retain not only excellent activity (an IC50 of 1.13 µM in the infected macrophage assay 
when run in quadruplicate with a standard deviation of 0.81 µM) and selectivity (an SI of 
23 over J774 macrophages) but a reasonable molecular weight (245 g/mol) and 
physicochemical properties (e.g. cLogP = 3.26, tPSA = 39). Work toward the further 
optimization of these compounds with optimal pharmacokinetic and pharmacodynamics 
properties as well as attempts to ascertain their target or mechanism of action is 
underway and will be reported in due course (Giulianotti et al., 2017).  
SNX2112 Analogs 
The activity of all analogs in a high content screening infected macrophage assay using 
transformed J774 murine macrophages is displayed in (Table 3.8). As expected, analog 
9 displayed potent and selective activity in the axenic amastigote assay, while the 
desmethylated 10 showed no activity at 25 µM. The HCS data indicates that the 
secondary and tertiary amines (17 and 16) are not particularly active, though it is 
noteworthy that the more substituted benzyl amine is the more active of the two which 
suggests a preference for greater substitution. This diminished activity pre-sumably 
arises from the physiological protonation of the amine under the assay conditions. More 
significantly, all of the amides showed reasonable HCS activity, and acetamide 18 was 
nearly equipotent with the parent (9). By contrast, sulfonamide 24 was considerably less 
active, and neither of the ureas showed any activity. It should also be noted that none of 
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the compounds prepared demonstrated any significant cytotoxicity, suggesting that the 
activity was specific to the Leishmania amastigotes. Notably, some analogs such as 18 
and 24 show considerably more activity in the infected macrophage assay than in our 
initial axenic amastigote assay. This type of behavior has previously been observed with 
opioid receptor antagonists (De Muylder et al., 2011), suggesting more than one target 
could be involved in the observed macrophage activity. With the exception of the 
number of rotatable bonds for 25, each of the compounds fell within acceptable 
parameters for oral bioavailability. We tested our most active N-linked analog 18 in a 
kinetic solubility assay to confirm that these modifications did not result in a deleterious 
effect on the physicochemical properties of the original lead, and were pleased to see 
that it demonstrates excellent solubility (> 490 µM) in PBS buffer (pH 7.4). We also 
sought to determine whether the antileishmanial activity could be tied to Hsp90 
inhibition. However, we were surprised to find that none of the new analogs prepared 
displayed significant inhibitory activity against human Hsp90 (Kim et al., 2004). In fact, 
unsubstituted analog 10 was more potent against Hsp90 than any of the compounds 
that were active in the antileishmanial assays. Among the possible explanations for this 
are these compounds are selective for the protozoan ortholog for Hsp90 (Hsp83) over 
human Hsp90 or that they are exerting their antileishmanial activity through a different 
mechanism (Kanwar et al., 2017). 
In summary, we have found a series of novel pyrazolo[3,4-c]pyrimidines based 
on the known Hsp90 agent SNX-2112 that show activity against Leishmania donovani in 
multiple assays. Significantly, several of these new compounds demonstrate more 
potent activity than the clinically used miltefosine in both of these assays, and excellent 
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selectivity over any observed cytotoxicity against human J774 macrophage cells. Work 
toward a better understanding of this activity, including the biochemical target, is 
currently underway. Although the starting point for this project was a compound that 
demonstrated an excellent ADME/PK profile, this is an early drug discovery project and 
we will continue to assess these parameters as we seek a lead compound with optimal 
properties (Kanwar et al., 2017). 
Mono-amidine Analogs 
 A library of aromatic diamidines and their analogues have been previously 
screened against Leishmania donovani, and novel DB745 and DB766 were discovered. 
Both compounds showed in vivo and in vitro exceptional antileishmanial activities. They 
also showed excellent activity against antimony-resistant Leishmania parasites. Despite 
that AIAs are structural analogs of cationic amidines (e.g., Pentamidine), they have 
different physiochemical properties and bioavailability (Wang et al., 2010). In an effort to 
discover more leishmanicidal analogs with improved properties, monoamidines 
compounds were synthesized, and their antileishmanial activity were evaluated against 
Leishmania donovani axenic amastigote assay and infected macrophage assay. Forty 
percent of the tested monoamidines analogs were potent leishmanicidal with 
submicromolar IC50 values in the infected macrophage model (Figure 3.9). In particular, 
DB2381 IC50 was among the most potent, with an IC50 of 0.15 µM and a selectivity of 
181 (Figure 3.10), which is substantially more active than miltefosine (Table 3.9). The 
data suggested that DB2381 is a promising hit candidate for drug development. Further 
work on DB2381 such as, in vivo antileishmanial activity and pharmacokinetics 
properties is needed in order to confirm its novel activity, and increase its chances to 
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undergo preclinical development and hope to become a treatment for visceral 
leishmaniasis. 
Quinazoline 
 Quinazolines have also been reported to have antileishmanial activity (Agarwal et 
al., 2009). As part of our effort to discover new classes of drugs to treat visceral 
leishmaniasis, in vitro activities of 76 quinazoline analogs were evaluated using axenic 
Leishmania donovani amastigote assay and infected macrophage assay (Table 3.10). 
Sixty percent of the tested analogues revealed activity in the infected macrophage 
assay, and only 20% were active in the axenic amastigote assay (Figure 3.11). Notably, 
QUI-1209 had an IC50 of 0.27 µM with selectivity index equals to 85. The lack of activity 
seen in some quinazolines in the axenic amastigotes assay and their high potency in 
the infected macrophage assay suggest that these compounds’ action could be cell-
mediated (Vermeersch et al., 2009). In vivo evaluation of QUI-1209 and 
pharmacokinetics need to be addressed to ensure its activity and physiochemical 
properties. The ease of synthesis and suitable physiochemical properties are features 
that make quinazolines an attractive class of candidate molecules for antileishmanial 
drug development. 
Thiazole  
Thiazoles based compounds have shown antileishmanial activity (Ardestani et 
al., 2012). Bhuniya et al. have synthesized a series of aminothiazoles and were 
screened for in vitro efficacy, microsomal stability, and solubility. Their results showed 
that this class of compounds has a promising submicromolar activity against visceral 
leishmaniasis (Bhuniya et al., 2015). In contrast, Thompson et al. screened 
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nitroimidazothiazoles and revealed no activity against Leishmania infantum (visceral 
leishmaniasis). Interestingly, it possessed potent activity against Trypanosoma cruzi 
(Chagas disease), (Thompson et al., 2017). The Bisht research group at USF 
synthesized a new series of thiazoles compounds. These compounds were screened 
against Leishmania donovani axenic amastigote model and infected macrophage model 
in our lab. Interestingly, 95% of all tested samples displayed activity against Leishmania 
donovani infected macrophage assay (Figure 3.12), with KBA-16 being among the most 
potent compound with an IC50 of 0.75 µM and a selectivity index of 237 (Figure 3.13), 
significantly more potent than miltefosine, which demonstrated an IC50 of 1.75 µM and a 
selectivity index of 28. Apparently, compound 16 exhibited no activity when tested 
against Leishmania donovani axenic amastigotes (Table 3.11). There are more than 
one possible explanation for this phenomenon. This compound might act as a prodrug 
where it gains its activity after entering the host cell. Or, it might be targeting the 
macrophage survival therefore leads to the death of the parasite.  
Primaquine-coumarin fluorescent probe (PQCP) 
As reported by McQueen et al. the developed primaquine coumarin- fluorescent 
probe (PQCP) demonstrated antimalarial potency similar to primaquine (PQ) and the 
probe was not toxic against HepG2 carcinoma cells. Interestingly, the developed probe 
decreased the toxicity of primaquine to the mammalian J774 cells. However, PQ was 
more active against Leishmania donovani axenic amastigote compared to PQCP (Table 
3.12), suggesting that the demonstrated activity of PQ against Leishmania donovani 
axenic amastigote might be due to its toxicity (McQueen et al., 2017). 
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 Our drug discovery effort led to the recognition of potent new classes and series 
of antileishmanial compounds with an exceptional submicromolar activity in the infected 
macrophage assay. Significantly more potent compared to miltefosine, the only 
available oral antileishmanial treatment. The identified chemical classes haven’t been 
reported as leishmanicidal in the field yet. However, further studies on these 
compounds such as in vivo evaluation, structure activity relationship (SAR), and 
pharmacokinetics are essential to develop new drugs that fit the need of leishmaniasis 
treatments.  
	  
	  
52	  
 
 
Figure 3.1: Compound 1 
(Kanwar et al., 2017). 
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Figure 3.2: Compound 2 
(Kanwar et al., 2017). 
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Figure 3.3: Preparation of Compounds 9-11 
(Kanwar et al., 2017).  
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(Kanwar et al., 2017). 
Figure 3.4: Minimized Poses of 11 in Hsp90 Showing The Geminal Methyl Groups 
Pointing Toward Hydrophobic Pockets 
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Figure 3.5: Preparation of Compounds 12- 17 
(Kanwar et al., 2017).  
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Figure 3.6: Preparation of Compounds 18-26 
(Kanwar et al., 2017).  
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Table 3.1: Leishmaniasis Activity of R1 Positional Scanning Study of Lib1 
 
 
ID# R1 AA IM ID# R1 AA IM 
Lib1.001 H 0% 2.5 Lib1.012  
 
 
  
 
0% 1.1 
Lib1.002  
 
 
  
 
69% >10 Lib1.013  
 
 
  
 
0% 0.9 
Lib1.003  
 
 
    
 
94% 1.2 Lib1.014  
 
 
 
 
99% 5.2 
Lib1.004  
 
 
  
 
91% >10 Lib1.015  
 
 
    
 
66% >10 
Lib1.005  
 
 
    
 
42% >10 Lib1.016  
 
 
  
 
37% 1.3 
Lib1.006  
 
 
  
 
86% 3.7 Lib1.017  
 
 
 
 
5% >10 
Lib1.007 
 
81% 0.7 Lib1.018 
 
23% 5.2 
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Table 3.1: (Continued) 
 
 
 
ID# R1 AA IM ID# R1 AA IM 
Lib1.008  
 
 
   
 
87% >10 Lib1.019  
 
 
   
 
0% 5.1 
Lib1.009 
 
 
14% 3.5 Lib1.020 
 
 
4% 5.3 
Lib1.010  
 
 
   
 
0% >10 Lib1.021 
 
 
 
 
   
 
100% 1.3 
Lib1.011  
 
 
   
 
34% >10 Lib1.022  
 
 
    
 
0% >10 
Lib1.023 
 
 
10% 5.2 Lib1.033 
 
 
0% 4.6 
Lib1.024  
 
 
    
 
31% >10 Lib1.034 
 
 
 
    
 
61% 1.2 
Lib1.025 
 
 
 
 
 
   
91% >10 Lib1.035 
 
 
 
 
   
 
100% 1.2 
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Table 3.1: (Continued) 
 
 
 
ID# R1 AA IM ID# R1 AA IM 
Lib1.026  
 
 
    
 
93% 0.9 Lib1.036  
 
 
    
 
100% >10 
Lib1.027 
 
 
 
 
   
 
0% 2.5 Lib1.037 
 
 
 
 
   
 
100% 2.4 
Lib1.028 
 
 
14% 1.7 Lib1.038 
 
 
100% 1.6 
Lib1.029  
 
 
    
 
61% 1.9 Lib1.039  
 
 
   
 
98% 1.2 
Lib1.030 
 
 
 
 
 
   
99% 3.6 Lib1.040 
 
 
 
 
 
   
63% >10 
Lib1.031 
 
 
 
    
 
100% 0.6 Lib1.041  
 
 
    
 
99% 1.2 
Lib1.032  
 
 
    
 
63% 2.9 Lib1.042  
 
 
    
 
99% 0.5 
 
AA is the % inhibition at 5 µM in the axenic amastigotes assay. IM is the IC50 in µM of 
the infected macrophage assay (Giulianotti et al., 2017).  
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Table 3.2: Leishmaniasis Activity of R2 Positional Scanning Study of Lib1 
 
 
ID# R2 AA IM ID# R2 AA IM 
Lib1.043 
 
 
 
 
   
 
91% >10 Lib1.056  
 
 
    
 
0% >10 
Lib1.044 
 
 
 
 
   
 
99% >10 Lib1.057  
 
 
    
 
3% >10 
Lib1.045 H 84% >10 Lib1.058  
 
 
    
 
23% 5.3 
Lib1.046 
 
 
 
 
   
 
100% 1.2 Lib1.059  
 
 
    
 
0% 5.4 
Lib1.047  
 
 
  
 
100% 5.1 Lib1.060 
 
 
 
 
 
   
29% >10 
Lib1.048  
 
 
    
 
0% 5.8 Lib1.061  
 
 
    
 
56% 5.2 
Lib1.049  
 
 
   
 
7% >10 Lib1.062 
 
 
 
 
   
 
98% 5.3 
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Table 3.2: (Continued) 
 
 
 
ID# R2 AA IM ID# R2 AA IM 
Lib1.050  
 
 
  
 
65% >10 Lib1.063  
 
 
   
 
99% 4.5 
Lib1.051  
 
 
    
 
0% >10 Lib1.064 
 
 
 
 
 
   
100% 5.1 
Lib1.052 
 
 
 
 
 
  
 
79% >10 Lib1.065  
 
 
    
 
95% >10 
Lib1.053 
 
 
 
 
 
   
96% >10 Lib1.066  
 
 
    
 
26% 3.8 
Lib1.054  
 
 
    
 
99% >10 Lib1.067  
 
 
    
 
99% >10 
Lib1.055  
 
 
    
 
97% >10 Lib1.068  
 
 
  
 
100% 0.6 
AA is the % inhibition at 5 µM in the axenic amastigotes assay. IM is the IC50 in µM of 
the infected macrophage assay (Giulianotti et al., 2017).   
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Table 3.3: Leishmaniasis Activity of R3 Positional Scanning Study of Lib1 
 
 
ID# R3 AA IM ID# R3 AA IM 
Lib1.069 H 0% 5.4 Lib1.080  
 
 
   
 
13% >10 
Lib1.070  
 
 
    
 
38% >10 Lib1.081  
 
 
   
 
21% 1.3 
Lib1.071 
 
 
 
 
   
 
63% 3.6 Lib1.082  
 
 
  
 
86% >10 
Lib1.072  
 
 
   
 
88% 0.6 Lib1.083  
 
 
 
 
   
3% 1.2 
Lib1.073 
 
 
 
 
   
 
11% 1.3 Lib1.084  
 
 
   
 
19% 1.3 
Lib1.074  
 
 
    
 
11% 1.3 Lib1.085  
 
 
  
 
1% 1.8 
Lib1.075  
 
 
   
 
25% 1.4 Lib1.086  
 
 
   
 
13% 4.8 
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Table 3.3: (Continued) 
 
 
 
ID# R3 AA IM ID# R3 AA IM 
Lib1.076 
 
 
 
 
   
 
57% 0.4 Lib1.087  
 
 
   
 
2% 1.3 
Lib1.077 
 
 
11% 6.1 Lib1.088 
 
 
12% 0.7 
Lib1.078  
 
 
    
 
9% 7 Lib1.089 
 
 
 
 
   
 
99% 5.1 
Lib1.079  
 
 
   
 
12% >10 Lib1.090  
 
 
    
 
0% 0.7 
Lib1.091 
 
 
7% 0.9 Lib1.101 
 
 
0% 1.4 
Lib1.092  
 
 
    
 
7% 5.1 Lib1.102 
 
 
 
    
 
9% 1.2 
Lib1.093 
 
 
 
 
 
   
58% 1.3 Lib1.103 
 
 
 
 
 
   
91% 1.3 
Lib1.094  
 
 
    
 
79% 1.8 Lib1.104  
 
 
    
 
94% 1.3 
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Table 3.3: (Continued) 
 
 
 
ID# R3 AA IM ID# R3 AA IM 
Lib1.095 
 
 
 
 
   
 
10% 2.7 Lib1.105 
 
 
 
 
   
 
11% >10 
Lib1.096 
 
 
21% 1.7 Lib1.106 
 
 
97% 3.5 
Lib1.097 	  
	  
	  
	  	     
 
15% 1.4 Lib1.107 	  
	  
	  
	  	    
 
42% >10 
Lib1.098 
	  
	  
	  
	  
	  
   
92% >10 Lib1.108 
	  
	  
	  
	  
	     
 
11% >10 
Lib1.099 	  
	  
	  
	  	    
 
100% 4.9 Lib1.109 	  
	  
	  
	  	     
 
90% 0.7 
Lib1.100 	  
	  
	  
	  	     
 
15% 1.2 Lib1.110 	  
	  
	  
	  	     
 
62% 2.7 
 
AA is the % inhibition at 5 µM in the axenic amastigotes assay. IM is the IC50 in µM of 
the infected macrophage assay (Giulianotti et al., 2017). 
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Table 3.4: Individually Synthesized Compound Activity 
 
 
# R1 R2 R3 AA 
(5 mM) 
AA 
(2.5 mM) 
IM 
IC50 (mM) 
Cytotoxicity 
IC50 (mM) 
SI 
6 A D G 26% 9% 0.6 48 81 
7 A D B 43% 0% >5 50 10 
8 A D H 100% 47% 0.3 28 89 
9 A E G 100% 37% 3.5 50 14 
10 A E B 75% 6% 1.8 50 28 
11 A E H 0% 0% 1.3 50 39 
12 A F G 6% 0% >5 50 10 
13 A F B 94% 0% 1.8 26 14 
14 A F H 97% 35% >5 46 9 
15 B D G 98% 68% 1.3 16 12 
16 B D B 99% 71% >5 15 3 
17 B D H 98% 78% 5 12 2 
18 B E G 97% 6% 1.3 50 38 
19 B E B 0% 0% 0.9 50 56 
20 B E H 0% 15% >5 34 7 
21 B F G 95% 97% 0.7 25 36 
22 B F B 95% 77% >5 24 5 
23 B F H 95% 70% 0.3 20 69 
24 C D G 94% 96% >5 32 6 
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Table 3.4: (Continued) 
 
 
 
# R1 R2 R3 
AA 
(5 mM) 
AA 
(2.5 mM) 
IM 
IC50 (mM) 
Cytotoxicity 
IC50 (mM) 
SI 
25 C D B 8% 11% 0.6 27 41 
26 C D H 0% 0% 0.9 22 25 
27 C E G 0% 0% 0.6 36 57 
28 C E B 99% 99% 2.6 32 13 
29 C E H 0% 0% 1.7 41 25 
30 C F G 85% 14% 2.5 26 11 
31 C F B 28% 0% >5 23 5 
32 C F H 57% 14% 0.9 17 20 
 
AA is the % inhibition in the axenic amastigotes assay. IM is the infected macrophage 
assay. Cytotoxicity is the cytotoxicity in J774 macrophage cells. SI is the selectivity 
index (cytotoxicity/IM) (Giulianotti et al., 2017). 
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Table 3.5: Analogues of 21 and 26 
 
 
ID * R1 R2 R3 IM 
IC50 
(mM) 
Cytotoxicity 
IC50 
(mM) 
SI 
21 S 
 
 
 
    
 
 
 
 
    
 
 
 
 
 
 
   
0.7 25 36 
33 R 
 
 
 
 
   
 
 
 
 
 
   
 
 
 
 
 
 
   
8.9 50 6 
34 S 
 
 
 
 
   
 
 
 
 
 
   
 
H 1.8 27 16 
35 S  
 
 
    
 
H 
 
 
 
 
 
   
3.5 6 2 
36 S H  
 
 
 
   
 
 
 
 
 
 
   
2.5 50 20 
37 S  
 
 
    
 
H H 5.2 24 5 
38 S H H  
 
 
   
 
10 13 1 
39 S H H H 4.8 50 10 
26 S 
 
 
 
0.9 22 25 
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Table 3.5: (Continued) 
 
 
 
ID * R1 R2 R3 IM 
IC50 (mM) 
Cytotoxicity 
IC50 (mM) 
SI 
40 R  
 
 
  
 
 
 
 
  
 
 
 
 
 
 
3.8 21 6 
41 S  
 
 
 
 
 
 
 
  
 
H 4.2 13 3 
42 S  
 
 
  
 
H  
 
 
 
 
0.7 23 33 
43 S H  
 
 
  
 
 
 
 
 
 
1.2 50 43 
44 S  
 
 
 
 
H H 3.5 50 14 
45 S H  
 
 
 
 
H 10 50 5 
46 S H H  
 
 
 
 
4.9 50 10 
47 S H H  
 
 
  
 
0.6 20 36 
IM is the infected macrophage assay. Cytotoxicity is the cytotoxicity in J774 macrophage cells. 
SI is the selectivity index (cytotoxicity/IM) (Giulianotti et al., 2017).	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Table 3.6: Analogs of 6− 8 
 
 
ID * R1 R2 R3 IM IC50 
(mM) 
Cytotoxicity 
IC50 (mM) 
SI 
6 S  
 
 
    
 
 
 
 
    
 
 
 
 
 
 
   
0.6 48 81 
7 S  
 
 
   
 
 
 
 
    
 
 
 
 
    
 
5.0 50 10 
8 S  
 
 
    
 
 
 
 
    
 
 
 
 
   
 
0.3 28 88 
48 R  
 
 
   
 
 
 
 
    
 
 
 
 
    
 
0.6 50 79 
49 S  
 
 
    
 
H 
 
 
 
 
 
   
2.5 9 4 
50 S  
 
 
   
 
H H 0.9 7 9 
51 S  
 
 
    
 
 
 
 
    
 
H 3.5 11 3 
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Table 3.6: (Continued) 
 
 
 
ID * R1 R2 R3 IM 
IC50 (mM) 
Cytotoxicity 
IC50 (mM) 
SI 
52 S H  
 
 
  
 
 
 
 
 
   
 
1.3 22 17 
53 S H  
 
 
 
   
 
H 5.0 50 10 
54 S  
 
 
    
 
H H 3.5 50 14 
55 S  
 
 
   
 
H H 0.9 50 56 
56 S  
 
 
  
 
H H 3.9 22 6 
57 S  
 
 
  
 
H H 1.2 16 13 
58 S 
	  
 
H H 1.8 19 10 
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Table 3.6: (Continued) 
 
 
 
ID * R1 R2 R3 IM 
IC50 
(mM) 
Cytotoxicity 
IC50 (mM) 
SI 
59	   S	   	  
	  
	  
	    
	  
H	   H	   0.6	   17	   28	  
60	   S	   	  
	  
	  
	    
	  
H	   H	   5.4	   14	   3	  
61	   S	   	  
	  
	  
	  	     
	  
H	   H	   4.4	   6	   1	  
 
IM is the infected macrophage assay. Cytotoxicity is the cytotoxicity in J774 
macrophage cells. SI is the selectivity index (cytotoxicity/IM)	  (Giulianotti et al., 2017). 
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Figure 3.7: Similarity of R1 and R3 
(Giulianotti et al., 2017).	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Table 3.7: Monoguanidines 
 
 
ID R1 R2 IM 
IC50 (µM) 
Cytotoxicity 
IC50 (µM) 
SI 
62  
 
 
  
 
 
 
 
    
 
2.4 15 6 
63  
 
 
  
 
H 4.8 15 3 
64  
 
 
    
 
 
 
 
    
 
1.1 25 23 
65  
 
 
   
 
H 10 8 1 
66  
 
 
    
 
 
 
 
    
 
4.7 12 3 
67  
 
 
   
 
 
 
 
    
 
0.6 6 10 
	  
IM is the infected macrophage assay. Cytotoxicity is the cytotoxicity in J774 
macrophage cells. SI is the selectivity index (cytotoxicity/IM) (Giulianotti et al., 2017).  
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Figure 3.8: Currently Used Antileishmaniasis Agents 
(1) Liposomal Amp B, (2) Sodium Stibogluconate, (3) Miltefosine, (4) Pentamidine, (5) 
Paromomycin (Giulianotti et al., 2017). 
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Table 3.8: Biological and Physicochemical Data For All Analogs 
Compound IC50 (µM) Lipinski/Physicochemical Properties (DruLiTo) 
AA IM J 774 
Cytotox 
MW cLogP H-bond 
acceptors 
H-bond 
donors 
tPSA Rotatable 
bonds 
Miltefosine 3.26 1.43 >50 408 8.7 4 0 55.43 20 
Radicicol 0.62 0.29 2.35 365 2.4 6 2 96.36 0 
1 0.42 0.61 < 0.06 437 2.9 7 4 49.74 5 
9 0.65 0.88 3.52 356 1.8 7 3 58.97 7 
10 > 25 > 10 > 50 332 0.7 7 3 58.97 7 
11 2.42 1.33 > 50 302 0.9 6 2 57.39 1 
16 2.29 6.33 > 50 418 0.9 8 3 62.21 9 
17 3.90 > 10 > 50 334 0.0 8 4 58.97 7 
18 13.9 1.06 > 50 374 -0.4 9 3 79.28 8 
19 6.43 3.54 > 50 386 -0.1 9 3 79.28 9 
20 1.90 3.54 37.3 398 0.2 9 3 79.28 9 
21 4.48 3.58 > 50 402 -0.9 10 3 88.51 10 
22 2.99 1.52 > 50 422 1.0 9 3 79.28 9 
23 2.60 1.75 26.3 446 1.1 9 3 79.28 9 
24 > 20 5.38 25.5 410 -0.6 10 3 104.73 8 
25 > 20 > 10 > 50 460 0.4 10 4 79.28 11 
26 > 20 > 10 > 50 376 -1.2 10 5 79.28 8 
Radicicol 0.62 0.29 2.35 365 2.4 6 2 96.36 0 
1 0.42 0.61 < 0.06 437 2.9 7 4 49.74 5 
9 0.65 0.88 3.52 356 1.8 7 3 58.97 7 
10 > 25 > 10 > 50 332 0.7 7 3 58.97 7 
11 2.42 1.33 > 50 302 0.9 6 2 57.39 1 
16 2.29 6.33 > 50 418 0.9 8 3 62.21 9 
17 3.90 > 10 > 50 334 0.0 8 4 58.97 7 
18 13.9 1.06 > 50 374 -0.4 9 3 79.28 8 
19 6.43 3.54 > 50 386 -0.1 9 3 79.28 9 
20 1.90 3.54 37.3 398 0.2 9 3 79.28 9 
21 4.48 3.58 > 50 402 -0.9 10 3 88.51 10 
22 2.99 1.52 > 50 422 1.0 9 3 79.28 9 
23 2.60 1.75 26.3 446 1.1 9 3 79.28 9 
24 > 20 5.38 25.5 410 -0.6 10 3 104.73 8 
25 > 20 > 10 > 50 460 0.4 10 4 79.28 11 
26 > 20 > 10 > 50 376 -1.2 10 5 79.28 8 
 
AA is for Axenic Amastigote, IM is for Infected Macrophage, Cytotox is for Cytotoxicity, 
and MW is for Molecular Weight (Kanwar et al., 2017). 
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Figure 3.9: Activity of Mono- Amidine Series in Multiple Assays 
40% were active in the infected macrophage assay, 40% were active in the axenic 
amastigotes assay and 21% were not toxic in the cytotoxicity assay. 
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Figure 3.10: Chemical Structure of DB2381 
Infected macrophage IC50= 0.15µM with SI=181. 
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Table 3.9: Activity of Mono- amidine Compounds in Multiple Assays (IC50 µM) 
Name Axenic Amastigotes 
 
Infected Macrophage 
 
Cytotoxicity IC50 
 
Infected Macrophage 
Selectivity Index 
DB183	   3.8   2.27   6.5   2.9  
DB2371	   14.7   0.29   50.0   172.4  
DB2375	   11.4   1.31   20.3   15.5  
DB2375A	   7.9   0.62   45.0   72.6  
DB2379	   20.0   0.31   50.0   161.3  
DB2380	   20.0   1.01   50.0   49.5  
DB2381	   3.4   0.15   27.2   181.1  
DB2385	   10.9   1.25   31.6   25.2  
DB2385A	   12.4   0.27   30.8   114.2  
DB2401	   12.2   0.27   50.0   185.2  
DB2402	   4.4   10   50.0   5.0  
DB2402A	   5.5   2.46   7.8   3.2  
DB2404	   17.0   3.56   50.0   14.0  
DB2404A	   6.5   5.42   25.3   4.7  
DB2405	   12.5   3.57   50.0   14.0  
DB2405A	   13.2   0.58   0.0   0.0  
DB2426	   20.0   1.18   50.0   42.4  
DB2436	   20   5.18   50.0   9.7  
DB2462	   9.8   0.62   4.3   7.0  
DB2463	   17.0   1.74   N/A   N/A  
DB2463A	   1.4   5.54   2.9   0.5  
DB2467	   6.9   10   50.0   5.0  
DB2486	   8.6   10   2.0   0.2  
DB2487	   11.2   1.25   N/A   N/A  
DB2487A	   5.9   4.3   4.1   1.0  
DB2491	   11.6   0.91   4.2   4.6  
DB2494	   13.1   1.35   3.0   2.2  
DB2494A	   10.4   2.51   N/A   N/A  
DB2506	   4.4   1.14   11.2   9.8  
DB2507	   14.1   0.84   33.7   40.1  
DB2524	   11.6   0.62   33.6   54.2  
DB2525	   20.0   10   50.0   5.0  
DB2551	   12.5   10   N/A   N/A  
DB2570	   5.8   0.23   N/A   N/A  
DB2579	   12.5   10   N/A   N/A  
DB2585	   12.3   0.64   N/A   N/A  
DB2593	   20.0   0.3   N/A   N/A  
DB2598 20.0 3.82 N/A N/A 
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Figure 3.11: Quinazolines Antileishmanial and Cytotoxicity Activity 
Sixty percent of the tested Quinazolines compounds showed activity in the infected 
macrophage model, while 20% of them were active in the axenic amastigotes model 
and 75% of them expressed no sign of cytotoxicity.  
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Table 3.10: Activity of Quinazolines (IC50 <1 µM in Infected Macrophage Model) 
Sample Name Axenic Amastigotes Cytotoxicity Infected Macrophage IM SI 
QUI-1209 5.2 23.1 0.27 85.3 
QUI-992 10.0 50.0 0.30 169.5 
QUI-923 10.0 50.0 0.30 166.7 
QUI-898 1.4 50.0 0.30 166.2 
QUI-1279 2.7 30.0 0.32 94.1 
QUI-776 10.0 50.0 0.56 90.1 
QUI-991 10.0 50.0 0.57 87.1 
QUI-882 10.0 50.0 0.62 81.0 
QUI-939 10.0 50.0 0.62 80.5 
QUI-1011 10.0 50.0 0.62 80.1 
QUI-773 10.0 44.5 0.66 67.9 
QUI-1210 10.0 25.0 0.67 37.3 
QUI-812 10.0 50.0 0.68 73.5 
QUI-1280 20.0 44.8 0.87 51.7 
QUI-998 10.0 50.0 0.87 57.5 
QUI 1251 N/A N/A 0.88 N/A 
QUI-1012 10.0 50.0 0.88 56.7 
QUI-960 8.4 30.2 0.88 34.2 
QUI-880 10.0 50.0 0.88 56.6 
QUI-1277 20.0 28.0 0.89 31.3 
QUI-1214 10.0 50.0 0.89 56.0 
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Table 3.11: Thiazole Antileishmanial Activity (IC50 µM) 
Sample 
Name 
Axenic 
Amastigote 
Cytotoxicity 
(J774) 
Infected 
Macrophage 
Infected Macrophage  
Selectivity Index 
KBA 1 75.2 96.3 13.52 7.12 
KBA 2 31.7 37.6 4.32 8.70 
KBA 3 47.8 87.1 6.26 13.93 
KBA 4 18.6 62.1 12.52 4.96 
KBA 5 43.1 126.2 33.78 3.74 
KBA 6 37.1 148.4 0.99 150.48 
KBA 7 67.6 168.9 8.32 20.31 
KBA 8 8.1 178.6 4.78 37.37 
KBA 9 4.5 119.0 12.75 9.33 
KBA 10 3.3 176.1 17.37 10.14 
KBA 11 18.3 144.9 1.80 80.74 
KBA 12 13.6 130.0 7.00 18.57 
KBA 13 18.0 84.9 6.54 12.98 
KBA 14 16.6 79.3 2.49 31.90 
KBA 15 74.6 12.8 13.37 0.95 
KBA 16 68.2 177. 0.75 237.52 
KBA 17 34.9 188.0 3.34 56.31 
KBA 18 49.9 185.2 2.24 82.78 
KBA 19 74.1 185.2 3.58 51.71 
Miltefosine 75.2 96.3 13.52 7.12 
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Figure 3.12: Active Thiazoles in Multiple Antileishmanial Assays 
All Samples were tested in infected macrophage (95% active), axenic amastigotes (79% 
active), and cytotoxicity assays (68% active not toxic). 
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Figure 3.13: Chemical structure of KBA 16 
Infected macrophage IC50= 0.75 µM and a selectivity index= 237. 
 
  
	  
	  
85	  
Table 3.12: Primaquine and Primaquine-Coumarin Fluorescent Probe IC50 Values 
in Multiple Assays (IC50 µg/ml) 
Sample Name Axenic 
Amastigote 
Cytotoxicity Selectivity Index 
PQ 4.62 2.28 0.49 
PQCP 11.4 25.2 2.21 
 
PQ and PQCP stand for primaquine and primaquine-coumarin fluorescent probe 
respectively (McQueen et al., 2017). 
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 Chapter Four: Antileishmanial Lead Optimization of Quinazolines 
(KVH-14) 
Abstract 
 Leishmaniasis is a disease caused by the parasite Leishmania. About 1.3 million 
new cases of leishmaniasis are reported annually causing approximately 30,000 deaths 
per year. Due to toxicity, high cost and resistance issues of available drugs, new and 
improved drugs are urgently needed. 
 Quinazolines are a class of compounds that have been tested against some 
Leishmania species. Some of these compounds exhibited promising activity against 
Leishmania donovani. Compound 23 (KVH-14 in this paper) has been evaluated in 
severe hamster visceral leishmaniasis model after demonstrating high in vivo efficacy in 
a previous conducted mouse study where it exhibited a 37% inhibition of parasite 
burden in the liver when given at 15 mg/kg for 5 consecutive days. In this study, KVH-14 
(23) was given orally at 30 mg/kg for 5 consecutive days and showed 89.9% reduction 
in liver parasitemia. The reference drug, miltefosine, reduced liver parasitemia by 95.6% 
when given at the same dose. 
Introduction 
Leishmaniasis is a parasitic disease transmitted by sand fly. The disease is 
endemic in approximately 98 countries worldwide with 1.3 million new cases reported 
annually (Lacerda, Pelegrini, de Oliveira, Vasconcelos, & Grossi-de-Sa, 2016). 
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Leishmaniasis is believed to be the 3rd most common parasitic disease after 
schistosomiasis and malaria in terms of morbidity with approximately 30,000 deaths per 
year (Zulfiqar, Shelper, & Avery, 2017). There are 29 species of Leishmania classified 
by their genetic and biochemical characterizations (Bethony et al., 2011). Leishmania 
donovani and Leishmania infantum are known to cause the fatal form visceral 
leishmaniasis. Drug resistance, toxicity and high cost of currently available treatment 
options create an urgent need for new drugs. 
Quinazolines are a class of compounds that have been reported to have activity 
against Leishmania (Bhattacharjee et al., 2002), (Agarwal, Sharma, Shakya, & Gupta, 
2009), (Kumar, Shakya, Gupta, Sarkar, & Sahu, 2009). A class of 2,4-
diaminoquinazolines showed an EC50 of 0.4 µM in Leishmania major amastigotes but 
high cytotoxicity poses significant issues in clinical use (Berman, King, & Edwards, 
1989). It is believed that quinazolines inhibit dihydrofolate reductase (Gilbert, 2002). 
Van Horn et al investigated the possibility of this mechanism of action and found that 
quinazolines were less active in the presence of folic acid, which supported the 
hypothesis of previous studies (Van Horn et al., 2014). 
Van Horn et al have tested N2, N4-disubstituted quinazolines 1 and 2 that 
showed some activity against Leishmania mexicana axenic amastigotes (Van Horn et 
al., 2014). These findings encouraged them to develop compounds structurally related 
to compounds 1 and 2 as described in the paper, which have been tested against 
Leishmania donovani and Leishmania amazonensis intracellular amastigote assays to 
select candidate molecules. Compounds that showed promising results were then 
tested for efficacy in a Leishmania donovani murine model to ensure their ability to 
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penetrate the host cell and inhibit the parasite growth without harming the 
macrophages. Two subseries compounds were prepared and tested to validate and 
optimize the activity of N2, N4-disubstituted quinazoline-2,4-diamines against 
Leishmania. The structure- activity relationship (SAR) study for the first subseries was 
focusing on N-2 and N-4 positions, while the second subseries focused on the benzenoid 
ring of the quinazoline scaffold. The purpose of the second series was to see the effect 
of the substituted benzenoid ring on the antileishmanial activity of these analogues. The 
substituted benzenoid ring compounds showed a range of single digit micro molar EC50 
values against Leishmania donovani where some of them exhibited no sign of toxicity 
against J774A.1 with a selectivity index greater than 10. Compounds 15, 16 and 23 
were the best candidate for an in vivo study due to their EC50 value against Leishmania 
donovani and showed low toxicity when tested against J774A.1 with a selectivity index 
greater than 40, (Van Horn et al., 2014).  
Previous In vivo Study (Acute Murine Visceral Leishmaniasis Model)  
To assess a tolerated dose for in vivo efficacy studies, the three compounds 
were given to uninfected mice at 30 mg/kg intraperitoneally.  Since compounds 16 and 
23 were toxic at 30 mg/kg, a lower concentration of 10 mg/kg and 15 mg/kg was 
administered intraperitoneally for 5 consecutive days in a murine visceral leishmaniasis 
model respectively. Compounds 15 and 16 did not show any inhibition in the parasites 
growth in treated mice compared to the vehicle control group, while compound 23 
showed a 37% inhibition in parasite burden in the liver when given at 15 mg/kg for 5 
consecutive days (Van Horn et al., 2014).  
The pharmacokinetics studies and the appropriate physiochemical properties of 
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compound 23 made it a suitable candidate for further investigation to develop a drug 
against Leishmania donovani (Van Horn et al., 2014). 
Materials and Methods 
Axenic Amastigotes Media Preparation and Culture 
L. donovani axenic amastigotes MHOM/SD/75/1246/130/ Khartoum (WR378) 
laboratory cell lines were cultured in a non-vented 25 cm2 tissue culture flask (Coning, 
Lowell, MA) using RPMI 1640 (Gibco) with 5.86 g/L MES (Sigma-Aldrich, St Louis, MO), 
7.5 g/L Hepes (Invitrogen Corp., Carlsbad, CA), 2 g/L sodium bicarbonate (Fisher 
Scientific, Pittsburg, PA), 100 µM Xanthine (Sigma-Aldrich, St Louis, MO), 10 mg/L 
Hemin (Sigma-Aldrich, St Louis, MO), 40 mg/L Tween-80 (Sigma-Aldrich, St Louis, 
MO), 5 g/L Trypton-Peptone (BD Bioscience, Sparks, MD), 1 % Penicillin- Streptomycin 
(Gibco, 10,000 u/ml), and 20 % 24 hours heat-inactivated FBS (Gibco). Media was set 
at a pH of 5.5.  L. donovani axenic amastigotes were cultured 1:5 three times per week 
and incubated at 37oC. 
Macrophage Media Preparation and Culture 
J774A.1 macrophages (ATCC, Manassas, VA) were cultured in a vented 75 cm2 
tissue culture flask using RPMI 1640 (Gibco), 1% Penicillin-Streptomycin (Gibco, 10,000 
u/ml), 10% 24 hour heat inactivated fetal bovine serum (Gibco) at a pH of 7.2. Twenty-
five ml of fresh media were added to culture flasks 3 times per week and cells were 
serially passaged biweekly. 
Leishmania donovani Axenic Amastigotes Drug Sensitivity Assay 
KVH-14 and control drug were tested against Leishmania donovani axenic 
amastigotes (MHOM/SD/75/1246/130) using the CellTiter 96 AQueous one-solution cell 
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proliferation assay (Promega, Madison, WI). In a 96 well drug plate (Costar, Assay 
Plate, 96 well with low Evaporation Lid, Flat Bottom, None-Treated, #3370) compounds 
were diluted in a series of 6 2-fold dilutions in media to produce a concentration range 
from 200µg/ml to 6.25µg/ml. Ten µL from each well was transferred to another 96 well 
plate (Costar, Assay Plate, 96 well with low Evaporation Lid, Flat Bottom, Tissue culture 
Treated, # 3628) and then 90uL of parasites in media in a 66,000 cell per well 
concentration was added to produce a final concentration range from 20µg/ml to 
625ng/ml.  The plates were then incubated at 37oC for 72 hours. Twenty µL of MTS {3-
(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-
tetrazolium}, (Promega, Madison, WI) solution was added to each well and incubated 
for an additional 4 hours. A Spectra Max M2e (Molecular Devices, Sunnyvale, Ca) was 
used to measure optical density (OD) at 490nm. Non-linear regression via Trifox 
software was used to determine IC50 values.  
Cytotoxicity Assay 
KVH-14 and control drug were tested against J774.A1 macrophages using the 
CellTiter 96 AQueous one-solution cell proliferation assay (Promega, Madison, WI). In a 
96 well drug plate (Costar, Assay Plate, 96 well with low Evaporation Lid, Flat Bottom, 
None-Treated, #3370) compounds were diluted in a series of 6 2-fold dilutions in media 
to produce a concentration range from 500µg/ml to 15.625µg/ml. Ten µL from each well 
was transferred to another 96 well plate (Costar, Assay Plate, 96 well with low 
Evaporation Lid, Flat Bottom, Tissue culture Treated, # 3628) and 90µL of macrophages 
in media in a 50,000 cell per well concentration was added to produce a final 
concentration range from 50µg/ml to 1.562 µg/ml. The plates were then incubated at 
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37oC, 5% Co2 for 72 hours. Twenty µL of MTS {3-(4,5-dimethylthiazol-2-yl)-5(3-
carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium} (Promega, Madison, WI) 
solution was added to each well and incubated for an additional 4 hours. A Spectra Max 
M2e (molecular Devices, Sunnyvale, Ca) was used to measure optical density (OD) at 
490nm. Non-linear regression via Trifox software was used to determine IC50 values.  
Infected Macrophage Drug Sensitivity Assay 
In a 384 well assay plate (CellCarrier-384 Black, Optically Clear Bottom, Tissue 
Culture Treated, Sterile, #6007550), 2000 J774A.1 macrophages were seeded and 
incubated for at least an hour to allow adherence. The plate was then washed with pre-
warmed media to remove the non-adherent cells. L. donovani axenic amastigotes were 
added to the plate in a ratio of 10:1 and incubated at 37 oC, 5% CO2 for 24 hours. The 
excess extracellular amastigotes were then washed away using pre-warmed media. 
KVH-14 and Miltefosine (control drug) were prepared in a 384-drug plate (Thermo 
Scientific™ Nunc™ 384-Well Clear Polystyrene Plates with Non /treated Surfaces, 
#242757) with a starting concentration of 10 µM or 10 µg/ml and serially diluted in a 1:2 
ratio. Drugs were then added to the assay plate and incubated at 37 oC, 5% CO2 for 72 
hours. After that, drugs were removed from the plate and the adhered cells were fixed 
with 2% paraformaldehyde (Alfa Aesar™ Paraformaldehyde, 16% w/v aq. soln., 
methanol free, #30525-89-4) and incubated for 15 minutes at room temperature. 
Fixative was then removed and cells were stained with 5 µM Draq5 (Thermo 
Scientific DRAQ5 fluorescent probe, DNA stain, #62251) and incubated for 5 minutes at 
room temperature. Stain was removed and fresh media was added to the plate. High 
content fluorescent imaging (Perkin Elmer Operetta) was used to capture images used 
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to perform cell counts. Harmony software calculated the number of amastigotes per 500 
macrophages in each well and used these counts to generate IC50 values. 
In all three assays, Miltefosine was used as a negative growth control drug and 
culture media was used as a positive growth control. 
In-vivo Study 
 A severe visceral leishmaniasis model was employed using 20 male Syrian 
hamsters ordered from Harlan laboratories (Livermore, CA). These hamsters were 4 
weeks old and weighed around 40 grams at the time of arrival. They were randomly 
stored into four groups, Miltefosine 30 mg/kg, control, KVH-14 30 mg/kg and KVH-14 10 
mg/kg. Cages with an average of 2 hamsters per cage were assigned for each group 
and maintained in a sterilized BSL2 facility. On day 0, each hamster was anesthetized 
by using Isoflurane (Isothesia, Butler Animal Health Supply, Dublin, OH) and 2x 108 
amastigotes suspended in amastigote media were inoculated into each hamster’s heart. 
Thirty days post infection each animal received treatment orally once daily according to 
its assigned group for 5 consecutive days. On day 36, the hamsters were sacrificed 
using CO2 asphyxiation. Liver, spleen and bone marrow were collected and weighed 
following the protocol described in (Srivastava, Sweat, Azizan, Vesely, & Kyle, 2013). A 
piece of liver and spleen were cut and taped into slides. Bone marrow was collected in 
100 µl media and smoothly spread on a slide as well. All slides were then methanol 
fixed and stained with 20% Gimsa stain. Microscopic examination of slides was used to 
determine parasite burden by calculating the number of amastigotes per 1000 
macrophages multiplied by the organ weight in grams as described by Stauber (Huff et 
al., 1958), expressing results as Leishman Donovan Units (Moreira et al., 2012). 
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Hamsters were handled according to local and federal regulations, and the 
University of South Florida Institutional Animal Care and Use Committee approved 
research protocols.  
Results and Discussion 
In vitro assays in drug discovery projects are designed to screen hundreds of 
samples using small amounts of compounds with low cost in a timely manner. In these 
assays, compounds usually have a direct impact on the parasites. In some cases, the 
action of some compounds is affected by the host immune system. Therefore, the 
results may not be reflected when tested in vivo (Gupta & Nishi, 2011). However, the 
infected macrophage assay is more relevant since it reflects the physiological 
conditions, as in the clinically relevant form of the disease situated within the host 
macrophages (De Rycker et al., 2013). Moreover, the infected macrophage assay can 
evaluate the ability of the compound to pass through the infected macrophage cell 
membrane and test its effect on both the parasites and macrophages, which reflects a 
strong correlation to the in vivo results. Seifert et al, evaluated the in vitro activity of 
antileishmanial reference drugs on different types of macrophages (mouse peritoneal 
macrophages, mouse bon marrow derived macrophages, human peripheral blood 
monocyte derived macrophages and differentiated THP-1). The activity of these drugs 
was significantly different among macrophage populations, which revealed that the 
activity is host cell dependent (Seifert, Escobar, & Croft, 2010). 
Compound KVH-14 showed no activity when tested in the axenic amastigotes 
assay. However, the same compound produced an IC50 of 1.4 µM in the infected 
macrophage model (Figure 4.1). According to Vermeersch et al, some compounds 
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might need to be metabolized by the macrophages to gain activity or maybe the 
macrophage is the target, leading to the destruction of amastigotes (Vermeersch et al., 
2009). An additional possibility is the compound accumulates to higher levels in the 
infected macrophage. 
 The finding of activity in the infected macrophage assay was confirmed in the 
severe hamster visceral leishmaniasis model in which KVH-14 inhibited parasitemia by 
89.9%, 77.10% and 77.86% in the liver, spleen and bone marrow, respectively, when 
given at 30 mg/kg for 5 consecutive days. Compound KVH-14 (KVH-5-97) also was 
evaluated at 10 mg/kg given orally for 5 consecutive days. At this dose, KVH-14 
reduced parasitemia by 60.51% in the liver, 47.36% in the spleen and 39.33% in bone 
marrow (Table 4.2), (Figure 4.2). Interestingly, in the acute murine visceral 
leishmaniasis model, KVH-14 reduced liver parasitemia by 37% when given at 15 mg/kg 
for 5 consecutive days. Therefore, KVH-14 activity was enhanced in the severe hamster 
model. The hamster visceral leishmaniasis model is considered to be more similar to 
human visceral leishmaniasis than to the murine model in terms of clinicopathological 
and immunopathological effects (Melby, Chandrasekar, Zhao, & Coe, 2001), which 
make KVH-14 an interesting antileishmanial candidate molecule. Seifert et al findings 
might explain the differences in the efficacy of KVH-14 between severe hamster model 
and acute murine model, as the activity of the drug is host cell dependent, which also 
could explain the efficacy differences on parasitemia between the 3 organs in the 
hamster model (Seifert et al., 2010). The outstanding activity of KVH-14 in the severe 
hamster model revealed that 2,4-quinazoline diamines is an important antileishmanial 
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candidate. More analogs of the same class need to be synthesized and evaluated in 
vivo. 
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Table 4.1: IC50 Values in Drug Sensitivity Assays (µM) 
Drugs 
 
Axenic 
amastigotes 
J774A.1 
Cytotoxicity 
Infected 
macrophage 
IM 
Selectivity 
index 
KVH-14 >20 45 1.4* 32 
Miltefosine 1.3* >50 1.79* 27 
 
* Mean of triplicate runs, IM= Infected macrophage. 
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Figure 4.1: Operetta Pictures of Treated Infected Macrophages 
Upper Right, 10 µM KVH-14 treated infected macrophages, upper left: 10 µM 
Miltefosine treated infected macrophage, lower left: Infected macrophage positive 
growth (no treatment- control), and lower right: macrophages only. 
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Table 4.2: Percentage of Parasite Inhibition in all Tissues in Severe Hamster 
Model 
Drugs Liver 
%inhibition 
Liver 
St. 
dev 
Spleen 
%inhibition 
Spleen 
St. dev 
Bone Marrow 
%inhibition 
Bone 
Marrow 
St. dev 
Miltefosine 
30 mg/kg 
95.59 1.28 92.22 2.67 96.70 2.28 
KVH 30 mg/kg 89.92 0.98 77.10 4.03 77.86 4.52 
KVH 10 mg/kg 60.51 7.18 47.36 10.2 39.33 2.28 
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Figure 4.2: Percentage of Parasite Inhibition in all Tissues in Severe Hamster 
Model 
30mg/kg KVH-14, 10mg/kg KVH-14 and 30mg/kg miltefosine. 
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 Chapter Five: Summary 
Introduction  
Leishmaniasis is one of the major neglected tropical diseases caused by 
Leishmania species parasites. There are more than 20 Leishmania species that cause 
the disease (Vijayakumar & Das, 2018). Transmission of leishmaniasis is caused by a 
bite of a female phlebotomine sand fly. There are more than 90 species are known to 
transmit leishmaniasis to human. Species of the genus Lutzomyia sand fly is found in 
the new world while species of Phlebotomus located in the old world (Bates et al., 
2015). There are several clinical forms of the disease that depends on the infective 
species of the parasite. Visceral leishmaniasis (VL) is considered the severe form that 
infects internal organs and causes hepatomegaly, splenomegaly, weight loss and, fever 
and anemia. This form can be fatal if left untreated (Jain & Jain, 2015). Around 350,000 
deaths from leishmaniasis reported annually worldwide (Kamhawi, 2017). An estimation 
of 0.2-0.4 million incidents of visceral leishmaniasis occurs annually. HIV- VL co-
infection has been reported by 35 countries, which increased the burden of visceral 
leishmaniasis (Sundar & Singh, 2016). Pentavalent antimonials, amphotericin B, 
miltefosine, and paromomycin are the available treatments for visceral leishmaniasis 
(Figure 5.1). However, the widespread of resistance to some of these drugs, toxicity, 
decreased efficacy and limited availability encouraged the search for new drugs to treat 
this devastating disease (Sundar & Chakravarty, 2015). 
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In an effort to discover an antileishmanial agent, we have been participating in 
different drug discovery projects and collaborating with many universities and institutes. 
From these collaborations, we were able to evaluate a new series of novel compounds 
from synthetic and natural product sources that can lead to promising drug candidates 
for treating visceral leishmaniasis.  
Natural Products 
Natural products are a rich source for the identification of new active drugs, 
which prove its effectiveness in treating several diseases. They represent 9 of 13 anti-
parasitic drugs approved by the U.S. Food and Drug Administration in the past 30 
years, emphasizing the vital role of this drug discovery resource for antileishmanial drug 
discovery research. Between the years 1981 to 2006, 1184 novel natural based drugs 
have been generated and 28% of them were from plants (Gutierrez-Rebolledo, Drier-
Jonas, & Jimenez-Arellanes, 2017). Catharanthus roseus is one of the most studied 
medicinal plants. Its alkaloids led to the discovery of the powerful anticancer drugs 
vinblastine and vincristine (Zhu, Zeng et al. 2014). Furthermore, marine microorganisms 
and macroorganisms are another rich sources that are not well studied as natural 
product source for drug discovery (Tchokouaha Yamthe et al., 2017). 
We tested Catharanthus roseus hairy root extracts against Leishmania donovani 
infected macrophage model. We also screened thousands of endophytic fungi extracts 
synthesized from mangrove plants in multiple Leishmania donovani assays. The initial 
screen demonstrated several active extracts that were then scaled up and tested for 
their activity. One fungal isolate was then scaled up and generated multiple pure 
compounds that led to the identification of Phomopsichromin C, which represented an 
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IC50 of 0.67µM in the infected macrophage model with an excellent selectivity over 
J774A.1. In addition we evaluated the activity of Antarctic deep-sea coral; 
(Keikipukalides and Furanocembrane diterpenes) in the Leishmania donovani infected 
macrophage model. Several pure compounds exhibited antileishmanial activity with 
Pukalide aldehyde being the most potent one (Table 5.1).  
Apparently, these sources have never been tested for their antileishmanial 
activity before. Thus, we were the first to identify novel antileishmanial hits from the 
Antarctic deep-sea coral, endophytic fungi from mangrove plants and C.roseus hairy 
root extracts.  
Synthetic Compounds 
By using Torry Pines scaffold ranking and positional scanning libraries, we were 
able to identify a series of guanidine-based compounds that possessed potent 
antileishmanial activity in multiple assays as well as selectivity over human 
macrophages, demonstrating that activity is unlikely to arise through simple 
promiscuous interactions. These compounds are structurally distinct from any of the 
currently used antileishmaniasis agents (Figure 5.1) and thus they represent a novel 
opportunity for lead optimization. We were subsequently able to use these libraries to 
focus in on compounds such as 64 that retain not only excellent activity (an IC50 of 1.13 
µM in the infected macrophage assay when run in quadruplicate with a standard 
deviation of 0.81 µM) and selectivity (an SI of 23 over J774 macrophages) but a 
reasonable molecular weight (245 g/mol) and physicochemical properties (e.g. cLogP = 
3.26, tPSA = 39). Work toward the further optimization of these compounds with optimal 
pharmacokinetic and pharmacodynamics properties as well as attempts to ascertain 
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their target or mechanism of action is underway and will be reported in due course 
(Giulianotti et al., 2017). 
We also have found a series of novel pyrazolo[3,4-c]pyrimidines based on the 
known Hsp90 agent SNX-2112 that show activity against Leishmania donovani in 
multiple assays. Significantly, several of these new compounds demonstrate more 
potent activity than the clinically used miltefosine in both of these assays, and excellent 
selectivity over any observed cytotoxicity against human J774 macrophage cells. Work 
toward a better understanding of this activity, including the biochemical target, is 
currently underway. Although the starting point for this project was a compound that 
demonstrated an excellent ADME/PK profile, this is an early drug discovery project and 
we will continue to assess these parameters as we seek a lead compound with optimal 
properties (Kanwar et al., 2017).   
Furthermore, mono-amidine analogue DB2381 exhibited an exceptional 
antileishmanial activity in the infected macrophage model (IC50= 0.15 µM, SI=181), 
substantially more potent than miltefosine.   
Moreover, we discovered a new class of quinazoline that has antileishmanial 
activity. Around 60% of screened quinazoline analogues possessed activity in the 
Leishmania donovani infected macrophage model. Notably, QUI-1209 displayed an 
IC50= 0.27 µM and selectivity index =85.  
Finally, we identified a new class of Thiazole with leishmanicidal activity against 
the infected macrophage model as well (KBA-16 IC50= 0.75 µM, SI=237). 
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A summary of the most potent compound in each class of molecules is represented in 
(Table 5.2). The discovery of new validated hits could speed up drug discovery projects 
and hopefully generate new drugs against visceral leishmaniasis. 
Antileishmanial Lead Optimization of Quinazolines  (KVH-14) 
So far, most of the reported drug discovery studies are mainly preliminary in vitro 
studies. Thus, in vivo studies are necessary in order to develop an effective 
leishmaniasis treatment (Singh, Mishra, Bajpai, Singh, & Tiwari, 2014).  
In a previous in vivo study, KVH-14 (compound 23) reduced liver parasitemia 
level by 37% in an acute murine model of visceral leishmaniasis model when given 
orally at 15mg/kg for 5 consecutive days. The pharmacokinetics studies and the 
appropriate physiochemical properties of compound 23 (KVH-14) made it a suitable 
candidate for further investigation to develop a drug against Leishmania (Van Horn et 
al., 2014). Thus, we evaluated the efficacy of KVH-14 in a severe hamster visceral 
leishmaniasis model. This compound decreased parasitemia level in the liver by almost 
90% when given orally at 30 mg/kg for 5 consecutive days.  Apparently, the reduction of 
parasitemia level was enhanced in the severe hamster visceral leishmaniasis model 
compared to the acute murine visceral leishmaniasis model. It is important to note that 
the hamster visceral leishmaniasis model is considered more similar to human visceral 
leishmaniasis than to the murine model in terms of clinicopathologically and 
immunopathologically (Melby, Chandrasekar, Zhao, & Coe, 2001), which make KVH-14 
a great antileishmanial candidate molecule. The outstanding activity of KVH-14 in the 
severe hamster model revealed that 2,4-quinazoline diamines is an important 
antileishmanial candidate. 
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Figure 5.1: Current Visceral Leishmaniasis Treatments 
Liposomal amphotericin B (1), Sodium stibogluconate (2), Miltefosine (3), Pentamidine 
(4), and Paromomycin (5). (Giulianotti et al., 2017). 
  
	  
	  
118	  
 
Table 5.1: Summary of Novel Natural Product-based Antileishmanial Hits 
Collaborator Institute Class Identified Novel 
Hit 
Infected 
Macrophage IC50 
and Selectivity 
Index 
Dr. Bill Baker 
 
Department 
of 
Chemistry, 
USF 
 
Mangrove 
Endophytic 
Fungal Extracts 
Phomopsichromin 
C 
 
0.67 µM, SI= 74 
Antarctic Deep 
Sea Coral 
(Plumarella 
delicatissima) 
 
Pukalide 
aldehyde 
 
1.9 µM, SI= 26 
Dr. Carolyn 
W.T. Lee-
Parsons 
Northeastern 
Univirsity 
C. roseus Hairy 
Root Extracts 
Sample 5 2.42 µg/ml, SI= 
20 
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Table 5.2: Summary of Novel Synthetic Antileishmanial Hits 
Collaborator Institute Class Identified Novel Hit Infected 
Macrophage 
IC50 and 
Selectivity 
Index 
Dr. Marc 
Giulianotti 
Torry Pine 
Institutes 
Guanidine Monoguanidine 64 1.13 µM, SI= 
23 
Dr. Jim Leahy Department 
of Chemistry, 
USF 
SNX2112 Compound 18 1.06 µM, SI= 
47 
Dr. David 
Boykin 
Georgia 
State 
University 
Mono-amidine DB2381 0.15 µM, SI= 
181 
Dr. Roman 
Manetsch 
Northeastern 
University 
Quinazoline QUI-1209 0.27 µM, SI= 
85 
Dr. Kirpal Bisht Department 
of Chemistry, 
USF 
Thiazole KBA-16 0.75 µM, SI= 
237 
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